Tokushima University / Educator and Researcher Directory --- Yoshimoto, Toshiaki

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Yosuke Iwakawa, Kouzou Yoshikawa, Koichi Okamoto, Tetsuji Takayama, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy, Surgical Case Reports, Vol.8, No.1, 70, 2022. (Summary) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare disease and characterized by a unique point mutation in the promoter 1B region of the adenomatous polyposis coli (APC) gene. There are two aims in surgery for GAPPS; the first is prophylactic gastrectomy, and the second is excising concurrent cancer. We performed robotic total gastrectomy (RTG) for four cases of GAPPS. Case 1 was a woman in her 40 s whose sister had died from gastric cancer. Mutational analysis revealed mutation of APC exon 1B. We performed prophylactic gastrectomy. Case 2 was a woman in her 30 s who had a mutation of APC exon 1B, and preoperative biopsy revealed suspected adenocarcinoma. Case 3 was a woman in her 40 s who was diagnosed with gastric cancer with multiple polyps in the stomach and a mutation of APC exon 1B. Case 4 was a woman in her 20 s in whom biopsy revealed low-grade dysplasia of a raised lesion. She had a mutation in APC exon 1B. We performed RTG with D1 + lymphadenectomy in all patients, and there were no intraoperative complications. Patients with GAPPS are mainly followed regularly with repeat biopsy, and tumors are detected in an early stage. As the safety of robotic surgery for the early gastric cancer is reported, RTG is an option for these patients. This is the first report of RTG for GAPPS patients. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01425-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35435526 ● Search Scopus @ Elsevier (PMID): 35435526 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01425-6 (DOI: 10.1186/s40792-022-01425-6, PubMed: 35435526)
2.	Shoko Yamashita, Masaaki Nishi, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuma Wada, Toshiaki Yoshimoto, Yosuke Iwakawa, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report., International Cancer Conference Journal, Vol.11, No.3, 196-200, 2022. (Summary) Gastric carcinomas with lymphoid stroma (GCLS) are characterized by prominent stromal infiltration of lymphocyte and account for 1-4% of gastric cancers. Although, osteoclast-like giant cells (OGC) have been reported in some GCLS, OGCs in gastric tumors is exceedingly rare. A 60-year-old woman presented to our hospital after the finding of a positive fecal blood test during a routine medical check. Esophagogastroduodenoscopy revealed a Type 0-III + IIc tumor in the middle part of the gastric body. Biopsy revealed a poorly differentiated tumor and she was referred to our department. Early phase computed tomography showed thickening of the wall in the middle of the gastric body and enlargement of nearby lymph nodes. Laparoscopic total gastrectomy was performed. Pathological examination revealed a hamartomatous inverted polyp (HIP) in the submucosal layer with tub2-por1 tumor in the HIP. Prominent lymphocytic infiltration and OGCs were found around the tumor. Immunohistochemical analysis showed that the tumor cells were negative for EBER, MLH-1, and MSH2, 6. These findings suggest that this tumor was a non-microsatellite instability (MSI)-high GCLS without Epstein-Barr virus (EBV) infection. The patient's postoperative course was uneventful and she was discharged 11 days after surgery. She remains well 3 years after surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-022-00547-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35669900 ● Search Scopus @ Elsevier (PMID): 35669900 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-022-00547-w (DOI: 10.1007/s13691-022-00547-w, PubMed: 35669900)
3.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara and Mitsuo Shimada : Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab., Annals of Gastroenterological Surgery, Vol.4, No.2, 151-155, 2020. (Summary) The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab-associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16 weeks and 24 days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n = 45) and patients treated with bevacizumab-free regimens as neoadjuvant therapy (n = 59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible. (Tokushima University Institutional Repository) ● Metadata: 116475 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12312 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32258980 ● Search Scopus @ Elsevier (PMID): 32258980 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12312 (Tokushima University Institutional Repository: 116475, DOI: 10.1002/ags3.12312, PubMed: 32258980)
4.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Takashi Iwata : Establishment of an evaluation system for non-technical skills in surgery : Surgeon and paramedical staff assessments., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 83-86, 2020. (Summary) Purposes : Non-technical skills contribute to safe and efficient team performance. The aim of this study was to clarify the importance of non-technical skills by a questionnaire and the usefulness of feedback to the operator. Method : A questionnaire was administered to the operator and paramedical staff for 404 operations. Total and individual scores were compared, and the effect of feedback was analyzed by comparison between pre-feedback and post-feedback. Results : The total score of the paramedical staff was 100 [full score] [n = 186], 90-99 [n = 133], and 80-89 [n = 47]. In all cases, the score of the paramedical staff was significantly better than that of the operator. After feedback, the rate of a score less than 80 was significantly decreased. In junior doctor cases with laparoscopy, feedback tended to have a positive effect. Conclusions : Questionnaires completed by both surgeons and paramedical staff are useful for identifying problems with non-technical skills. J. Med. Invest. 67 : 83-86, February, 2020. (Keyword) Allied Health Personnel / Clinical Competence / Communication / Decision Making / Evaluation Studies as Topic / General Surgery / Humans / Leadership / Patient Care Team / Surgeons / Surveys and Questionnaires (Tokushima University Institutional Repository) ● Metadata: 114757 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.83 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378623 ● Search Scopus @ Elsevier (PMID): 32378623 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.83 (Tokushima University Institutional Repository: 114757, DOI: 10.2152/jmi.67.83, PubMed: 32378623)
5.	Toshiaki Yoshimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Hiroki Teraoku, Yoshimi Bando and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy., Anticancer Research, Vol.38, No.1, 501-507, 2018. (Summary) We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective. (Keyword) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Fibroblast Growth Factor 4 / Hepatectomy / Hepatitis B / Humans / Liver Neoplasms / Male / Middle Aged / Niacinamide / Phenylurea Compounds / Retrospective Studies / Salvage Therapy / Sorafenib / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12250 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29277815 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039796842 (DOI: 10.21873/anticanres.12250, PubMed: 29277815, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Chie Takasu, Masaaki Nishi, Kozo Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative evaluation to determine the difficulty of No. 6 lymphadenectomy in laparoscopic gastrectomy., BMC surgery, Vol.24, No.1, 69, 2024. (Summary) Laparoscopic gastrectomy (LG) requires a long learning curve because of the complicated surgical procedures. Infrapyloric (No. 6) lymph node dissection (LND) is one of the difficult procedures in LG, especially for trainees. This study investigated the impact of the prediction of the difficulty of No. 6 LND. We retrospectively reviewed the preoperative computed tomography (CT) images and individual operative video records of 57 patients who underwent LG with No. 6 LND to define and predict the No. 6 LND difficulty. To evaluate whether prediction of the difficulty of No. 6 LND could improve surgical outcomes, 48 patients who underwent laparoscopic distal gastrectomy were assessed (30 patients without prediction by a qualified surgeon and 18 patients with prediction by a trainee). The anatomical characteristic that LND required > 2 cm of dissection along the right gastroepiploic vein was defined as difficulty of No. 6 LND. Of the 57 LG patients, difficulty was identified intraoperatively in 21 patients (36.8%). Among the several evaluated anatomical parameters, the length between the right gastroepiploic vein and the right gastroepiploic artery in the maximum intensity projection in contrast-enhanced CT images was significantly correlated with the intraoperative difficulty of No. 6 LND (p < 0.0001). Surgical outcomes, namely intraoperative minor bleeding, postoperative pancreatic fistula, and drain amylase concentration were not significantly different between LG performed by a trainee with prediction compared with that by a specialist without prediction. Preoperative evaluation of the difficulty of No. 6 LND is useful for trainees, to improve surgical outcomes. (Keyword) Humans / Retrospective Studies / Stomach Neoplasms / Lymph Node Excision / Laparoscopy / Gastrectomy / Postoperative Complications (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-024-02349-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38389108 ● Search Scopus @ Elsevier (PMID): 38389108 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-024-02349-8 (DOI: 10.1186/s12893-024-02349-8, PubMed: 38389108)
2.	Chie Takasu, Yuji Morine, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Role of stromal PD-L1 expression in colorectal liver metastasis., BMC cancer, Vol.24, No.1, 97, 2024. (Summary) The outcomes of immune checkpoint blockade for colorectal cancer (CRC) treatment are unsatisfactory. Furthermore, the efficacy of immune checkpoint blockade for liver metastasis of various cancer is poor. Here, we investigated the relationship between stromal programmed death-ligand 1 (PD-L1) expression and the prognosis of patients with colorectal cancer liver metastasis (CRLM). The present study enrolled 84 CRLM patients who underwent surgery (R0) for CRC. Immunohistochemistry was performed to analyze stromal PD-L1 expression in CRLM. Stromal PD-L1 was expressed in 52.3% of CRLM samples, which was associated with fewer not optimally resectable metastases (p = 0.04). Stromal PD-L1 also tended to associate with a lower tumor grade (p = 0.08). Stromal PD-L1-positive patients had longer overall survival (p = 0.003). Multivariate analysis identified stromal PD-L1 expression (p = 0.008) and poorer differentiation (p < 0.001) as independent prognostic indicators. Furthermore, stromal PD-L1 expression was correlated to a high number of tumor-infiltrating lymphocytes (TILs). Stromal PD-L1- and low TIL groups had shorter OS than stromal PD-L1 + and high TIL groups (46.6% vs. 81.8%, p = 0.05) Stromal PD-L1-positive patients had longer disease-free survival (DFS) (p = 0.03) and time to surgical failure (p = 0.001). Interestingly, stromal PD-L1 expression was positively related to the desmoplastic subtype (p = 0.0002) and inversely related to the replacement subtype of the histological growth pattern (p = 0.008). Stromal PD-L1 expression may be a significant prognostic marker for CRLM. (Keyword) Humans / B7-H1 Antigen / Colorectal Neoplasms / Immune Checkpoint Inhibitors / Liver Neoplasms / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-024-11869-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38233811 ● Search Scopus @ Elsevier (PMID): 38233811 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-024-11869-8 (DOI: 10.1186/s12885-024-11869-8, PubMed: 38233811)
3.	Takayuki Noma, Masaaki Nishi, Chie Takasu, Yuuma Wada, Kozo Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuko Miyakami, Kengo Atsumi, Hisanori Uehara and Mitsuo Shimada : Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report., International cancer conference journal, Vol.13, No.1, 11-16, 2023. (Summary) We here present a case report of a patient with Stage IV gastric cancer with peritoneal metastasis (P1, CY1) who underwent conversion surgery after a successful response to chemotherapy (S-1 + oxaliplatin + nivolumab). The patient was a woman in her 60 s. Her chief complaint was epigastric pain. Upper gastrointestinal endoscopy showed Type 4 advanced carcinoma on the lesser curvature of the gastric body. Biopsy showed Group 5 (poorly differentiated adenocarcinoma) and HER2 was negative. Staging laparoscopy revealed seeding in the round ligament of the liver (P1) and adenocarcinoma cells in ascites (CY1). Ten courses of chemotherapy (S-1 + oxaliplatin + nivolumab) were administered, after which contrast-enhanced computed tomography showed that the primary tumor had shrunk and seeding was no longer detectable. Upper gastrointestinal endoscopy revealed scar-like changes. A second staging laparoscopy revealed that ascites cytology was negative and a biopsy of the round ligament of the liver showed no malignant cells (P0, CY0). Conversion surgery comprising laparoscopic total gastrectomy with D2 lymph node dissection and resection of the round ligament of the liver was performed. The postoperative course was uneventful. Histopathological examination of the resected specimen revealed no tumor cells in the gastric mesentery or the round ligament of the liver. The pathological diagnosis was gastric cancer [M, U, L, Less, Ant, Post, type4, T3(SS), N0, M0 (H0, P0, CY0), ypStage IIA]. Adjuvant chemotherapy (S-1) was commenced. The patient is still alive 7 months later with no evidence of recurrence. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-023-00628-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38187176 ● Search Scopus @ Elsevier (PMID): 38187176 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-023-00628-4 (DOI: 10.1007/s13691-023-00628-4, PubMed: 38187176)
4.	Masaaki Nishi, Yuuma Wada, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach., BMC Surgery, Vol.23, No.1, 128, 2023. (Summary) Robotic surgery (RS) has been rapidly adopted for gastric cancer and adenocarcinoma of the esophagogastric junction (AEG). However, the utility of RS for Siewert type II/III AEG remains unclear. Forty-one patients who underwent either transhiatal RS (n = 15) or laparoscopic surgery (LS) (n = 26) for Siewert type II/III AEG were enrolled in this study. The surgical outcomes of the two groups were compared. In the entire cohort, there were no significant intergroup differences in the operative time, blood loss volume, or number of retrieved lymph nodes. The length of the postoperative hospital stay was shorter in the RS group than in the LS group (14.20 ± 7.10 days vs. 18.73 ± 17.82 days, respectively; p = 0.0388). The morbidity rate (Clavien-Dindo grade ≥ 2) was similar between the groups. In the Siewert II cohort, there were no significant intergroup differences in short-term outcomes. In the entire cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (91.67% vs. 91.48%, N.S.) or 3-year disease-free survival rate (91.67% vs. 91.78%, N.S.), respectively. Likewise, in the Siewert type II cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (80.00% vs. 93.33%, N.S.) or 3-year disease-free survival rate (80.00% vs. 94.12%, N.S.), respectively. Transhiatal RS for Siewert II/III AEG was safe and contributed to similar short-term and long-term outcomes compared with LS. (Keyword) Humans / Robotic Surgical Procedures / Retrospective Studies / Gastrectomy / Adenocarcinoma / Stomach Neoplasms / Laparoscopy / Esophagogastric Junction / Esophageal Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02045-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37194030 ● Search Scopus @ Elsevier (PMID): 37194030 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02045-z (DOI: 10.1186/s12893-023-02045-z, PubMed: 37194030)
5.	Kozo Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuma Wada and Toshiaki Yoshimoto : The application of enhanced recovery after surgery in total gastrectomy: a propensity score-matched analysis., World journal of surgical oncology, Vol.21, No.1, 148, 2023. (Summary) This study aimed to investigate the feasibility and safety of our enhanced recovery after surgery protocol including early oral intake and omitting nasogastric tube (NGT) placement after total gastrectomy. We analyzed 182 consecutive patients who underwent total gastrectomy. The clinical pathway was changed in 2015, and patients were divided into 2 groups (conventional group and modified group). Postoperative complications, bowel movement, and postoperative hospital stays were compared in the two groups in all cases and propensity score matching (PSM). Flatus and defecation were significantly earlier in the modified group compared with those in the conventional group (flatus: 2 (1-5) days vs 3 (2-12) days, p = 0.03; defecation: 4 (1-14) days vs 6 (2-12) days p = 0.04). The postoperative hospital stay was 18 (6-90) days in the conventional group and 14 (7-74) days in the modified group (p = 0.009). Days until discharge criteria were met were earlier in the modified group compared with that in the conventional group (10 (7-69) days vs 14 (6-84) days p = 0.01). Overall and severe complications occurred in nine patients (12.6%) and three patients (4.2%) in the conventional group and twelve patients (10.8%) and four patients (3.6%) in the modified group, respectively (p = 0.70 and p = 0.83) in all cases. In PSM, there is no significant difference between the two groups concerning the postoperative complications (overall complication 6 (12.5%) vs 8 (16.7%) p = 0.56, severe complications 1 (2%) vs 2 (4.2%) p = 0.83). Modified ERAS for total gastrectomy may be feasible and safe. (Keyword) Humans / Enhanced Recovery After Surgery / Propensity Score / Flatulence / Stomach Neoplasms / Retrospective Studies / Gastrectomy / Length of Stay / Postoperative Complications / Treatment Outcome / Laparoscopy (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-023-03034-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37194033 ● Search Scopus @ Elsevier (PMID): 37194033 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-023-03034-5 (DOI: 10.1186/s12957-023-03034-5, PubMed: 37194033)
6.	Toshiaki Yoshimoto, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Takayuki Noma and Mitsuo Shimada : Surgical Outcomes of Gastrectomy in Hemodialysis Patients with Gastric Cancer., The American surgeon, Vol.89, No.12, 6328-6330, 2023. (Keyword) Humans / Stomach Neoplasms / Retrospective Studies / Laparoscopy / Gastrectomy / Treatment Outcome / Renal Dialysis (Link to Publication Site) ● Publication site (DOI): 10.1177/00031348231173970 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37132264 ● Search Scopus @ Elsevier (PMID): 37132264 ● Search Scopus @ Elsevier (DOI): 10.1177/00031348231173970 (DOI: 10.1177/00031348231173970, PubMed: 37132264)
7.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kozo Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Yuhei Waki, Toshiaki Yoshimoto, Takayuki Noma and Mitsuo Shimada : Transanal lateral lymph node dissection with intraoperative hologram support in low rectal cancer., Surgical endoscopy, Vol.37, No.7, 5414-5420, 2023. (Summary) In Japan, the standard treatment for stage II/III advanced low rectal cancer is total mesorectal excision plus lateral lymph node dissection (LLND). There are also recent reports on the use of transanal LLND. However, the transanal anatomy is difficult to understand, and additional support tools are required to improve the surgical safety. The present study examined the utility of holograms with mixed reality as an intraoperative support tool for assessing the complex pelvic anatomy. Polygon (stereolithography) files of patients' pelvic organs were created and exported from the SYNAPSE VINCENT imaging system and uploaded into the Holoeyes MD virtual reality software. Three-dimensional images were automatically converted into patient-specific holograms. Each hologram was then installed into a head mount display (HoloLens2), and the surgeons and assistants wore the HoloLens2 when they performed transanal LLND. Twelve digestive surgeons with prior practice in hologram manipulation evaluated the utility of the intraoperative hologram support by means of a questionnaire. Intraoperative hologram support improved the surgical understanding of the lateral lymph node region anatomy. In the questionnaire, 75% of the surgeons answered that the hologram accurately reflected the anatomy, and 92% of the surgeons answered that the anatomy was better understood by simulating the hologram intraoperatively than preoperatively. Moreover, 92% of the surgeons agreed that intraoperative holograms were a useful support tool for improving the surgical safety. Intraoperative hologram support improved the surgical understanding of the pelvic anatomy for transanal LLND. Intraoperative holograms may represent a next-generation surgical tool for transanal LLND. (Keyword) Humans / Treatment Outcome / Lymph Node Excision / Lymph Nodes / Rectal Neoplasms / Dissection (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-023-09977-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37017769 ● Search Scopus @ Elsevier (PMID): 37017769 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-023-09977-w (DOI: 10.1007/s00464-023-09977-w, PubMed: 37017769)
8.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : Stapler insertion angle toward the esophagus reduces the incidence of early postoperative Roux stasis syndrome after distal gastrectomy in minimally invasive surgery., BMC Surgery, Vol.23, No.1, 54, 2023. (Summary) Roux stasis syndrome (RSS) after Roux-en-Y (RY) reconstruction significantly prolongs the hospital stay and decreases the quality of life. The purpose of the present study was to evaluate the incidence of RSS in patients who underwent distal gastrectomy for gastric cancer and to identify the factors related to the development of RSS after mechanical RY reconstruction in minimally invasive surgery (MIS). This study included 134 patients who underwent distal gastrectomy in MIS with mechanical RY anastomosis. RSS was defined as the presence of symptoms such as nausea, vomiting, or abdominal fullness, and the confirmation of delayed gastric emptying on imaging or gastrointestinal fiber testing. Clinical data were checked, including body mass index, operative procedure, age, sex, operative time, blood loss volume, extent of lymph node dissection, final stage, stapler insertion angle, method of entry hole closure. The relationship between the incidence of RSS and these factors was analyzed. RSS occurred in 24 of 134 patients (17.9%). RSS occurred significantly more frequently in patients with D2 lymphadenectomy than in patients with D1 + lymphadenectomy (p = 0.04). All patients underwent side-to-side anastomosis via the antecolic route. The incidence of RSS was significantly greater in patients with a stapler insertion angle toward the greater curvature (n = 20, 22.5%) versus the esophagus (n = 4, 8.9%) (p = 0.04). The multivariate logistic regression model revealed that the stapler insertion angle to the greater curvature is identified as independent risk factor for RSS (OR 3.23, 95%Cl 1.01-10.3, p = 0.04). Stapler insertion angle toward the esophagus may reduce the incidence of early postoperative RSS rather than toward the greater curvature. (Keyword) Humans / Incidence / Quality of Life / Gastrectomy / Anastomosis, Roux-en-Y / Esophagus / Stomach Neoplasms / Minimally Invasive Surgical Procedures / Postoperative Complications (Tokushima University Institutional Repository) ● Metadata: 118879 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-01954-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36906525 ● Search Scopus @ Elsevier (PMID): 36906525 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-01954-3 (Tokushima University Institutional Repository: 118879, DOI: 10.1186/s12893-023-01954-3, PubMed: 36906525)
9.	Hideya Kashihara, Mitsuo Shimada, Kozo Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Impact of the Pre-operative Neutrophil-lymphocyte Ratio as the Predictive Marker of Post-operative Weight Loss and Improving Diabetes in Sleeve Gastrectomy., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 140-144, 2023. (Summary) The aim was to investigate the impact of the neutrophil-lymphocyte ratio (NLR) in sleeve gastrectomy (SG). 15 obese patients were enrolled in this study ; mean body weight (BW) 127.5kg ; mean body mass index (BMI) 46.7kg/m. 10 of these were diabetics who underwent a SG. The impact of the pre-operative NLR on the percentage of excess weight loss (%EWL) and remission of diabetes 1 year post-operative were examined. The %EWL at 1 year post-operative were 46.3%. Improvements were also evident in the diabetes at 1 year post-operative : complete remission (CR) 40%, partial remission (PR) 20% and Improve 40%. Comparing pre-operative NLR in %EWL<50% and ≧50% in 1 year post-operative, <50% was 2.64 and ≧50% was 2.03. The NLR in CR and PR was significantly lower than that in Improve. The pre-operative NLR may be a predictive marker of weight loss and improving diabetes after SG. J. Med. Invest. 70 : 140-144, February, 2023. (Keyword) Humans / Obesity, Morbid / Treatment Outcome / Neutrophils / Retrospective Studies / Laparoscopy / Diabetes Mellitus / Weight Loss / Body Mass Index / Gastrectomy (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.140 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164710 ● Search Scopus @ Elsevier (PMID): 37164710 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.140 (DOI: 10.2152/jmi.70.140, PubMed: 37164710)
10.	Masaaki Nishi, Yuma Wada, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Shinichiro Yamada, Toshiaki Yoshimoto and Mitsuo Shimada : Prognostic impact of frailty after gastrectomy in elderly gastric cancer patients., The journal of medical investigation : JMI, Vol.70, No.3.4, 423-429, 2023. (Summary) Frailty plays a crucial role in cancer patients who have received surgery in this recent aging society. We aimed to investigate frailty as a prognostic factor in elderly gastric cancer (GC) patients who underwent curative gastrectomy. We analyzed 86 elderly (over 75 years old) GC patients who underwent curative gastrectomy. Patients were assigned to two groups;frailty group (n=29) and no-frailty group (n=57). Clinicopathological values were compared between the two groups. The OS rate of the frailty group was significantly poorer than that of the no-frailty group (5-yr OS rate;frailty group 52.49% vs. no-frailty group 74.87%, p<0.05). Multivariate analysis of the OS showed that frailty tended to be significant prognostic factor (p=0.09). The DFS rate of the frailty group was significantly poorer than that of the no-frailty group (5-yr DFS rate;frailty group 42.30% vs. no-frailty group 71.55%, p<0.05). Multivariate analysis of the DFS showed that frailty tended to be significant prognostic factor (p=0.14). We identified the clinical impact of frailty prognostic factor for elderly GC patients who underwent gastrectomy. J. Med. Invest. 70 : 423-429, August, 2023. (Keyword) Humans / Aged / Prognosis / Stomach Neoplasms / Frailty / Aging / Gastrectomy / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.423 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940527 ● Search Scopus @ Elsevier (PMID): 37940527 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.423 (DOI: 10.2152/jmi.70.423, PubMed: 37940527)
11.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy., BMC Cancer, Vol.22, No.1, 1263, 2022. (Summary) The role of the immune system in locally advanced rectal cancer (LARC) following preoperative chemoradiotherapy (CRT) has been widely investigated in recent years. This study examined the prognostic significance of indoleamine-pyrrole 2,3-dioxygenase (IDO) expression in patients with LARC who received preoperative CRT. Ninety patients with LARC who underwent preoperative CRT and curative resection were enrolled. IDO and programmed death-ligand 1 (PD-L1) expression was evaluated by immunohistochemistry. Clinicopathological factors did not significantly differ between patients with positive or negative IDO expression, excluding the correlation of positive IDO expression with better tumor differentiation (p = 0.02). IDO expression was not associated with pathological response (p = 0.44), but it was associated with PD-L1 expression. The 5-year overall survival (OS) rate was significantly worse in the IDO-positive group than in the IDO-negative group (64.8% vs. 85.4%, p = 0.02). Univariate analysis identified IDO and PD-L1 expression (p = 0.02), surgical procedure (p = 0.01), final pathological stage (p = 0.003), lymph node metastasis (p < 0.001), and lymphatic invasion (p = 0.002) as significant prognostic factors for OS. Multivariate analysis revealed that IDO expression (HR: 7.10, p = 0.0006), surgical procedure (HR: 5.03, p = 0.01), lymph node metastasis (HR: 2.37, p = 0.04) and lymphatic invasion (HR: 4.97, p = 0.01) were independent prognostic indicators. Disease-free survival was not correlated with IDO or PD-L1 expression. IDO expression in patients with LARC who received preoperative CRT could be a potential prognostic indicator. IDO expression could be a useful marker for specifying individual treatment strategies in LARC. (Keyword) Humans / B7-H1 Antigen / Chemoradiotherapy / Lymphatic Metastasis / Neoadjuvant Therapy / Prognosis / Rectal Neoplasms / Indoleamine-Pyrrole 2,3,-Dioxygenase (Tokushima University Institutional Repository) ● Metadata: 118002 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-022-10357-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36471264 ● Search Scopus @ Elsevier (PMID): 36471264 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-10357-1 (Tokushima University Institutional Repository: 118002, DOI: 10.1186/s12885-022-10357-1, PubMed: 36471264)
12.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Visualization of the pelvic nerves using magnetic resonance imaging for rectal cancer surgery., Surgical Endoscopy, 2022. (Summary) This study evaluated the visualization of the pelvic nerves using magnetic resonance imaging (MRI) combined with computed tomography (CT) to synthesize three-dimensional (3D) reconstruction images of the pelvic organs. The CT and MRI scans were performed for patients with rectal cancer who underwent surgery. The out-of-phase image of LAVA-Flex was used to identify the pelvic nerves. The images of the pelvic nerves were extracted from the MRI scans, and those of the arteries and rectum and pelvis were extracted from the CT scans. Each extracted organ image was used to synthesize 3D reconstruction images. The MRI scan allowed adequate visualization of the pelvic splanchnic nerves, inferior hypogastric plexus, and obturator nerves. The comparison of 3D reconstruction images and intraoperative findings showed matched images. We visualized the pelvic nerves using MRI and synthesized 3D reconstruction images of the pelvic organs. Preoperative confirmation of the location of the pelvic organs is important to prevent unanticipated injury during rectal cancer surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-022-09771-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36418640 ● Search Scopus @ Elsevier (PMID): 36418640 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-022-09771-0 (DOI: 10.1007/s00464-022-09771-0, PubMed: 36418640)
13.	Chie Takasu, 調憲, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : オンライン時代は女性医師キャリア形成の追い風となる, The Japanese Journal of Gastroenterological Surgery, Vol.55, No.11, 729-732, 2022. (Summary) 新型コロナウイルス感染症の拡大が,これまで停滞していた医師の働き方改革の推進へとつながっている.その中でも,学会のオンライン化は医師の働き方に大きな変化をもたらした.学会のリモート参加は,自宅に居ながら参加でき,地方からも参加しやすく,移動時間と費用の大きな削減となる.オンデマンド配信は,時間・場所にかかわらず学ぶ機会を得られる非常に有効なツールとなる.また,学会の委員活動など,習慣的に行われていた対面での会議が,現在はほぼ遠隔で行われている.これまで時間的制約により,積極的に学会活動に手を挙げることができなかった女性医師の同分野での活躍推進が期待される.特に子育て中の女性医師にとって,オンライン化はワーク・ライフ・バランスを維持しながらキャリアを形成していく有効なツールとなりうる.この変化を逃さず女性活躍推進へとつなげるための,オンライン学会(ハイブリット形式)の継続を強く要望したい.(著者抄録) (Keyword) 育児労働衛生女性医師抄録作成と索引作成職歴の移動テレビ会議テレワーキングヒト女 (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.2022.sr005 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390857226420483072 ● Search Scopus @ Elsevier (DOI): 10.5833/jjgs.2022.sr005 (DOI: 10.5833/jjgs.2022.sr005, CiNii: 1390857226420483072)
14.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer., Oncology Letters, Vol.24, No.5, 415, 2022. (Summary) Previous studies have revealed the usefulness of neoadjuvant chemotherapy (NAC) followed by surgery for clinical stage III gastric cancer (GC). The tumor volume at the primary tumor site (PT) is sometimes difficult to measure because of the luminal structure; therefore, evaluation of the lymph node (LN) response to NAC may help to more accurately predict survival outcomes. The present study therefore evaluated the LN response to NAC for prediction of survival outcomes in patients with GC. The study involved 160 patients with clinical stage III GC who underwent NAC (n=14) and upfront surgery (n=146). PT and LN responses to NAC were evaluated, various clinicopathological factors were evaluated and Cox proportional hazard regression analyses were performed to determine survival outcomes. Overall survival (OS) and disease-free survival (DFS) were not significantly different between patients who underwent NAC and those who underwent upfront surgery (OS, P=0.71; DFS, P=0.50). However, although there were no significant differences in PT responses, patients classified as LN non-responders to NAC had a significantly worse prognosis compared with patients classified as LN responders in terms of DFS (PT, P=0.93; LN, P<0.01) and OS (PT, P=0.84; LN, P<0.01). Moreover, a higher neutrophil-lymphocyte ratio tended to be associated with poor DFS [univariate: hazard ratio (HR)=4.23, P=0.06; multivariate: HR=6.45, P=0.04]. Finally, an LN response to NAC was significantly better for prediction of recurrence (univariate, HR=7.79, 95% confidence interval=1.16-63.51, P=0.02; multivariate, HR=7.44, P=0.01). Overall, the current study revealed the clinical importance of the LN response to NAC for predicting survival outcomes in patients with GC. These findings highlight the potential clinical impact of optimizing treatment strategies to improve the selection and management of patients. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13535 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245824 ● Search Scopus @ Elsevier (PMID): 36245824 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13535 (DOI: 10.3892/ol.2022.13535, PubMed: 36245824)
15.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Computed tomography texture analysis for the prediction of lateral pelvic lymph node metastasis of rectal cancer., World Journal of Surgical Oncology, Vol.20, No.1, 281, 2022. (Summary) This study aimed to investigate the usefulness of computed tomography (CT) texture analysis in the diagnosis of lateral pelvic lymph node (LPLN) metastasis of rectal cancer. This was a retrospective cohort study of 45 patients with rectal cancer who underwent surgery with LPLN dissection at Tokushima University Hospital from January 2017 to December 2021. The texture analysis of the LPLNs was performed on preoperative CT images, and 18 parameters were calculated. The correlation between each parameter and pathological LPLN metastasis was evaluated. The texture parameters were compared between pathologically metastasis-positive LPLNs and metastasis-negative LPLNs. A total of 40 LPLNs were extracted from 25 patients by preoperative CT scans. No LPLNs could be identified in the remaining 19 patients. Eight of the 25 patients had pathologically positive LPLN metastasis. Extracted LPLNs were analyzed by the texture analysis. Pathologically metastasis-positive LPLNs had significantly lower mean Hounsfield unit, gray-level co-occurrence matrix (GLCM) energy, and GLCM Entropy_log2 values, and a significantly larger volume than pathologically metastasis-negative LPLNs. Multivariate analysis revealed that the independent predictive factors for LPLN metastasis were volume (a conventional parameter) (odds ratio 7.81, 95% confidence interval 1.42-43.1, p value 0.018) and GLCM Entropy_log2 (a texture parameter) (odds ratio 12.7, 95% confidence interval 1.28-126.0, p value 0.030). The combination of both parameters improved the diagnostic specificity while maintaining the sensitivity compared with each parameter alone. Combining the CT texture analysis with conventional diagnostic imaging may increase the accuracy of the diagnosis of LPLN metastasis of rectal cancer. (Keyword) Humans / Lymph Node Excision / Lymph Nodes / Lymphatic Metastasis / Rectal Neoplasms / Retrospective Studies / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 118078 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-022-02750-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36057660 ● Search Scopus @ Elsevier (PMID): 36057660 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-022-02750-8 (Tokushima University Institutional Repository: 118078, DOI: 10.1186/s12957-022-02750-8, PubMed: 36057660)
16.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Syoko Yamashita : Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study., International Journal of Clinical Oncology, Vol.27, No.9, 1439-1449, 2022. (Summary) This study was performed to assess the impact of osteopenia on chemotherapy-induced neutropenia and the prognosis for patients treated with FOLFOXIRI for colorectal cancer. In total, 77 patients who underwent FOLFOXIRI for un-resectable metastatic and advanced colorectal cancer were retrospectively evaluated. Osteopenia was evaluated by the bone mineral density, which was measured using the average pixel density of the trabecular bone in the 11th thoracic vertebra by computed tomography before the introduction of chemotherapy. The relationship between osteopenia and neutropenia was evaluated. Progression-free survival and overall survival of patients with osteopenia and patients with neutropenia were evaluated. Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0.002). The multivariate analysis showed that osteopenia was a significant independent predictive factor for grade ≥ 3 neutropenia (p = 0.016). There was no significant difference in progression-free survival or overall survival between patients with and without osteopenia. Patients with grade ≥ 3 neutropenia tended to have a higher progression-free survival rate than others (p = 0.059). The overall survival rate was significantly higher in patients with grade ≥ 3 neutropenia than in others (p = 0.011). Osteopenia might be a predictor of chemotherapy-induced neutropenia, and neutropenia might be a prognostic factor for progression-free survival and overall survival in patients with colorectal cancer treated with FOLFOXIRI. (Keyword) Antineoplastic Agents / Antineoplastic Combined Chemotherapy Protocols / Bevacizumab / Bone Diseases, Metabolic / Camptothecin / Colorectal Neoplasms / Fluorouracil / Humans / Leucovorin / Neutropenia / Organoplatinum Compounds / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02199-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35908137 ● Search Scopus @ Elsevier (PMID): 35908137 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02199-5 (DOI: 10.1007/s10147-022-02199-5, PubMed: 35908137)
17.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, Yosuke Iwakawa, Noriko Yokota and Mitsuo Shimada : Intraoperative holographic image-guided surgery in a transanal approach for rectal cancer., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.6, 2579-2584, 2022. (Summary) Urethral injury is one of the most important complications in transanal total mesorectal excision (TaTME) in male patients with rectal cancer. The purpose of this study was to investigate holographic image-guided surgery in TaTME. Polygon (stereolithography) files were created and exported from SYNAPSE VINCENT, and then uploaded into the Holoeyes MD system (Holoeyes Inc., Tokyo, Japan). After uploading the data, the three-dimensional image was automatically converted into a case-specific hologram. The hologram was then installed into the head mount display, HoloLens (Microsoft Corporation, Redmond, WA). The surgeons and assistants wore the HoloLens when they performed TaTME. In a Wi-Fi-enabled operating room, each surgeon, wearing a HoloLens, shared the same hologram and succeeded in adjusting the hologram by making simple hand gestures from their respective angles. The hologram contributed to better comprehension of the positional relationships between the urethra and the surrounding pelvic organs during surgery. All surgeons were able to properly determine the dissection line. This first experience suggests that intraoperative holograms contributed to reducing the risk of urethral injury and understanding transanal anatomy. Intraoperative holograms have the potential to become a new next-generation surgical support tool for use in spatial awareness and the sharing of information between surgeons. (Keyword) Dissection / Humans / Laparoscopy / Male / Postoperative Complications / Proctectomy / Rectal Neoplasms / Rectum / Surgery, Computer-Assisted / Transanal Endoscopic Surgery (Link to Publication Site) ● Publication site (DOI): 10.1007/s00423-022-02607-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35840706 ● Search Scopus @ Elsevier (PMID): 35840706 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-022-02607-4 (DOI: 10.1007/s00423-022-02607-4, PubMed: 35840706)
18.	Yuuma Wada, Masaaki Nishi, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative nutrition and exercise intervention in frailty patients with gastric cancer undergoing gastrectomy., International Journal of Clinical Oncology, Vol.27, No.9, 1421-1427, 2022. (Summary) The frailty was associated with the worse surgical outcomes and poor prognosis in several cancers. Therefore, we aimed to identify the usefulness of nutrition and exercise intervention (NEI) in frailty patients with GC. We analyzed 58 frailty patients with GC who underwent radical surgery. Among these, 15 patients were performed NEI by nutritional and rehabilitation support team. We compared the surgical outcomes between NEI and non-NEI groups with frailty patients and evaluated the nutrition and rehabilitation markers in pre- and post-NEI groups. The postoperative complication of NEI groups was 6.7% and less than that of non-NEI groups (p = 0.08). The mean postoperative hospital stay of NEI groups was 13.0 ± 1.0 days for NEI groups and significantly shorter than that of non-NEI groups (p = 0.03). The NLR was 4.3 ± 0.6 for pre-NEI and significantly improved by NEI between pre- and post-NEI (p = 0.03). We identified the clinical importance of NEI for improving the surgical outcomes in frailty patients with GC. Our findings highlight the potential clinical impact of optimizing treatment strategies to select and manage the frailty patients. (Keyword) Exercise Therapy / Frailty / Gastrectomy / Humans / Postoperative Complications / Preoperative Care / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02202-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35771395 ● Search Scopus @ Elsevier (PMID): 35771395 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02202-z (DOI: 10.1007/s10147-022-02202-z, PubMed: 35771395)
19.	Shuhai Chen, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Akiko Nakamoto, Tohru Sakai and Mitsuo Shimada : Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts., Oncology Letters, Vol.24, No.1, 236, 2022. (Summary) Sudachitin is a polymethoxylated flavone found in the peel of , a unique specialty citrus fruit in Tokushima Prefecture, Japan. Previous reports have demonstrated that sudachitin has anti-inflammatory and metabolic regulatory activities. However, to the best of our knowledge, no studies have explored whether sudachitin can act as an antitumor therapeutic agent by regulating metabolic functions in the tumor microenvironment. In the present study, cell proliferation and cytotoxicity assays were used to determine whether sudachitin inhibited the growth of liver cancer and pancreatic carcinoma, cholangiocarcinoma and colorectal cancer cells and to compare its toxicity against normal fibroblasts and induced cancer-associated fibroblasts (CAFs). Using lactate assays and reverse transcription-quantitative PCR, the effects of sudachitin on glycolysis in CAFs were investigated. The effects of CAFs on malignant tumor cells were evaluated using cell proliferation, wound healing and invasion assays. As result, sudachitin inhibited various types of tumor cells with different half-maximal inhibitory concentrations. Treatment with 50 µM sudachitin for 48 h suppressed tumor and CAFs proliferation but was not cytotoxic against normal fibroblasts. This dose also inhibited glycolysis in CAFs and, thus, diminished their pro-tumorigenic activities. Overall, the present study revealed that sudachitin has promise as a safe and widely available natural antitumor adjuvant. (Tokushima University Institutional Repository) ● Metadata: 118072 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13356 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35720469 ● Search Scopus @ Elsevier (PMID): 35720469 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13356 (Tokushima University Institutional Repository: 118072, DOI: 10.3892/ol.2022.13356, PubMed: 35720469)
20.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Chiharu Nakasu and Mitsuo Shimada : Pincer Approach to Gastrosplenic Ligament in Robotic Total Gastrectomy for Gastric Cancer., Journal of Gastrointestinal Surgery, Vol.26, No.7, 1552-1555, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Ligaments / Retrospective Studies / Robotic Surgical Procedures / Robotics / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s11605-022-05356-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35578006 ● Search Scopus @ Elsevier (PMID): 35578006 ● Search Scopus @ Elsevier (DOI): 10.1007/s11605-022-05356-3 (DOI: 10.1007/s11605-022-05356-3, PubMed: 35578006)
21.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Vascular variations encountered during laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer: a retrospective cohort study., BMC Surgery, Vol.22, No.1, 170, 2022. (Summary) Laparoscopic surgery for cancer located in the transverse colon or splenic flexure is difficult because of vascular variability in this region and adjacent vital organs such as the pancreas, spleen, and duodenum. This retrospective cohort study involved 51 patients who underwent laparoscopic surgery for colon cancer at Tokushima University Hospital from July 2015 to December 2020. Variations of the middle colic artery (MCA), left colic artery (LCA), middle colic vein (MCV), and first jejunal vein (FJV) and short-term outcomes of laparoscopic surgery in patients with each vascular variation were evaluated. Variations of the MCA, LCA, MCV, and FJV were classified into four, three, five, and three patterns, respectively. The short-term outcomes of laparoscopic surgery for transverse colon cancer in patients with MCA variations and those with FJV variations were evaluated, and no significant difference was found in the operation time, blood loss, postoperative complication rate, time from surgery to start of dietary intake, or time from surgery to discharge among the different variations. Additionally, no significant differences were found in the short-term outcomes of laparoscopic surgery for descending colon cancer in patients with LCA variations. Preoperative assessment of vascular variations may contribute to the stability of short-term outcomes of laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer. (Keyword) Colectomy / Colon, Descending / Colon, Transverse / Colonic Neoplasms / Humans / Laparoscopy / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 118005 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01603-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35538458 ● Search Scopus @ Elsevier (PMID): 35538458 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01603-1 (Tokushima University Institutional Repository: 118005, DOI: 10.1186/s12893-022-01603-1, PubMed: 35538458)
22.	Yosuke Iwakawa, Kouzou Yoshikawa, Koichi Okamoto, Tetsuji Takayama, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy., Surgical Case Reports, Vol.8, No.1, 70, 2022. (Summary) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare disease and characterized by a unique point mutation in the promoter 1B region of the adenomatous polyposis coli (APC) gene. There are two aims in surgery for GAPPS; the first is prophylactic gastrectomy, and the second is excising concurrent cancer. We performed robotic total gastrectomy (RTG) for four cases of GAPPS. Case 1 was a woman in her 40 s whose sister had died from gastric cancer. Mutational analysis revealed mutation of APC exon 1B. We performed prophylactic gastrectomy. Case 2 was a woman in her 30 s who had a mutation of APC exon 1B, and preoperative biopsy revealed suspected adenocarcinoma. Case 3 was a woman in her 40 s who was diagnosed with gastric cancer with multiple polyps in the stomach and a mutation of APC exon 1B. Case 4 was a woman in her 20 s in whom biopsy revealed low-grade dysplasia of a raised lesion. She had a mutation in APC exon 1B. We performed RTG with D1 + lymphadenectomy in all patients, and there were no intraoperative complications. Patients with GAPPS are mainly followed regularly with repeat biopsy, and tumors are detected in an early stage. As the safety of robotic surgery for the early gastric cancer is reported, RTG is an option for these patients. This is the first report of RTG for GAPPS patients. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01425-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35435526 ● Search Scopus @ Elsevier (PMID): 35435526 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01425-6 (DOI: 10.1186/s40792-022-01425-6, PubMed: 35435526)
23.	Toshiaki Yoshimoto, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Shohei Okikawa and Kouzou Yoshikawa : Blue light irradiation inhibits the growth of colon cancer and activation of cancer-associated fibroblasts., Oncology Reports, Vol.47, No.5, 2022. (Summary) Irradiation with a specific wavelength of light using light-emitting diodes (LEDs) has various effects on cells and organisms. Recently, the antitumor effects of visible blue light on tumor cells were reported; however, the mechanism and effects on the tumor microenvironment remain unclear. Human colon cancer cells (HCT-116) were injected into the rectal wall of nude mice. Tumors were irradiated with a 465-nm LED light at 30 mW/cm for 30 min. Tumor volumes and the expression levels of opsin 3 (Opn3), autophagy-related factors, cancer-associated fibroblast (CAF) markers, and programmed cell death 1-ligand (PD-L1) were measured. Additionally, human intestinal fibroblasts were cultured in HCT116-conditioned medium (CM) to prepare CAFs. CAFs were divided into an LED group and a control group, and the effect of the LED light on CAF activation in colon cancer cells was examined. Irradiation with blue LED light suppressed tumor growth; Opn3 expression was localized to the cell membrane in the LED group. Irradiated tumors exhibited increased autophagy-related gene expression. Furthermore, in the LED group, TGF-β and α-SMA expression levels in the fibroblasts were decreased. Regarding CAFs, α-SMA and IL-6 expression levels were decreased in the LED group. HCT-116 cells cultured in CAF-CM with LED irradiation showed no enhanced migration or invasion. In the HCT-116 cells cultured in CM of CAFs irradiated with LED, the relative increase in PD-L1 expression was lower than that noted in the CAF-CM without LED irradiation. Blue LED light may have a direct antitumor effect on colon cancer and also an inhibitory effect on CAFs. (Keyword) Animals / B7-H1 Antigen / Cancer-Associated Fibroblasts / Cell Movement / Cell Proliferation / Colonic Neoplasms / HCT116 Cells / Humans / Light / Mice / Mice, Nude / Rod Opsins / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 118073 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8315 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35417035 ● Search Scopus @ Elsevier (PMID): 35417035 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8315 (Tokushima University Institutional Repository: 118073, DOI: 10.3892/or.2022.8315, PubMed: 35417035)
24.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Risk factors for postoperative ileus after diverting loop ileostomy closure., BMC Surgery, Vol.22, No.1, 131, 2022. (Summary) Postoperative ileus is one of the most common complications after diverting loop ileostomy closure. Some reports have investigated the risk factors for postoperative complications or ileus after ileostomy closure; however, these studies did not evaluate the index surgery sufficiently. In this study, we evaluated the risk factors, including the details of the index surgery, for ileus after diverting ileostomy closure. This was a retrospective study of patients who underwent ileostomy closure following index surgery for rectal cancer. Patients who developed postoperative ileus [POI (+)] and patients who did not [POI (-)] after ileostomy closure were compared. Sixty-eight patients were evaluated and were divided into two groups: POI (+) (n = 11) and POI (-) (n = 57), and the groups were compared. There were no significant differences in the details of the index surgery, operative procedure, transanal total mesorectal excision, lateral lymph node dissection, operating time, or blood loss. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery were significantly higher in the POI (+) group. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery may increase the risk of postoperative ileus after ileostomy closure. (Keyword) Humans / Ileostomy / Ileus / Postoperative Complications / Rectal Neoplasms / Retrospective Studies / Risk Factors (Tokushima University Institutional Repository) ● Metadata: 118004 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01583-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35392877 ● Search Scopus @ Elsevier (PMID): 35392877 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01583-2 (Tokushima University Institutional Repository: 118004, DOI: 10.1186/s12893-022-01583-2, PubMed: 35392877)
25.	Masaaki Nishi, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 【外科代謝栄養と東洋医学:漢方による周術期管理へのサポート】大建中湯による周術期管理のサポート, The Japanese Journal of Surgical Metabolism and Nutrition, Vol.56, No.2, 59-61, 2022. (Summary) 近年では漢方の分子生物学的な作用機序の解明が進み，臨床においても質の高いランダム化比較試験により漢方の有用性が明らかになってきた．現在では大建中湯を含む多くの漢方製剤が広く臨床の現場で用いられている．大建中湯は乾姜，人参，山椒の3つの生薬に膠飴を加えた漢方で，外科領域においては癒着性イレウスや麻痺性イレウス，過敏性腸症候群，クローン病などを適応とし，消化管運動促進作用，腸管血流増加作用，抗炎症作用などが報告されている．近年では，食道・胃・大腸・肝臓・膵臓・肝移植外科それぞれの領域でランダム化試験が実施され，大建中湯の周術期管理における有効性が証明されている．また分子生物学的なメカニズムについても解明がすすみ，現在，大建中湯は消化管外科・肝胆膵外科の分野を問わず消化器外科全般における周術期管理のkey drugとして位置付けられている．本稿では消化器外科領域における大建中湯による周術期管理のサポートについて概説する．(著者抄録) (Keyword) 消化管運動消化器外科バクテリアルトランスロケーション周術期管理 *大建中湯(薬理学,治療的利用) 伊東細胞腫瘍微小環境ヒト (Link to Publication Site) ● Publication site (DOI): 10.11638/jssmn.56.2_59 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.56.2_59 (DOI: 10.11638/jssmn.56.2_59)
26.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Yosuke Iwakawa : The correlation of immunoscore and frailty in colorectal cancer., International Journal of Clinical Oncology, Vol.27, No.3, 528-537, 2022. (Summary) The Immunoscore is a useful prognostic and predictive factor for colorectal cancer. Frailty predicts overall and recurrence-free survival following resection of colorectal cancer, and the immunosuppressive state of frailty might affect tumor progression. This study investigated the relationship between the Immunoscore and frailty in colorectal cancer. This retrospective study included patients who underwent radical surgery for stage II and III colorectal cancer (n = 108). Patients were divided into frail (n = 11) and non-frail (n = 97) groups, and low (IS0-2) (n = 70) and high (IS3-4) Immunoscore groups (n = 38), for comparison. American Society of Anesthesiologists physical status was higher, tumor diameter was larger, number of well-differentiated tumors was higher, albumin was lower, 5-year overall survival (OS) was lower (frail group: 50.0%, non-frail group: 90.5%, p < 0.001) and 5-year disease-free survival (DFS) was lower (frail group: 36.4%, non-frail group: 75.2%, p = 0.024) in the frail than in the non-frail group. Left colon cancer was more, 5-year OS was lower (IS0-2 group: 82.0%, IS3-4 group: 96.7%, p = 0.040) and 5-year DFS was lower (IS0-2 group: 66.3%, IS3-4 group: 83.3%, p = 0.043) in the IS0-2 than in the IS3-4 group. The Immunoscore was lower in the frail than in the non-frail group. Immunoscore and frailty are prognostic and predictive factors in colorectal cancer, and they are correlated with each other. The immunosuppressive state from frailty might affect this correlation. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Disease-Free Survival / Frailty / Humans / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02096-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34846645 ● Search Scopus @ Elsevier (PMID): 34846645 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02096-3 (DOI: 10.1007/s10147-021-02096-3, PubMed: 34846645)
27.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Shoko Iwahashi : Usefulness of a stepwise training program for laparoscopic gastrectomy., Asian Journal of Endoscopic Surgery, Vol.15, No.1, 121-127, 2022. (Summary) Laparoscopic gastrectomy (LG) is a complicated procedure with a long learning curve. This study was performed to investigate the usefulness of our stepwise training program for LG for improving the quality of the surgery. The stepwise training method comprised the following four steps: (1) basic training using a dry box and checking by mentors; (2) advanced training, including the use of animals and cadavers; (3) clinical experience, including standardization and preoperative three-dimensional simulation; and (4) self-assessment and feedback. In total, 153 patients who underwent curative gastrectomy for gastric cancer were included in this study. The operative time gradually decreased for both laparoscopic distal gastrectomy (LDG) (2013, 395inutes; 2017, 278inutes; P < .001; = -0.68) and laparoscopic total gastrectomy (LTG) (2013, 476inutes; 2017, 319inutes; P < .001; = -0.56). The blood loss volume gradually decreased for both LDG (2013, 43.0 mL; 2017, 18.6 mL; P < .005; = -0.30) and LTG (2013, 143.8 mL; 2017, 13.5 mL; P < .005; = -0.41). Our stepwise training program contributes to reduce operation time and blood loss in LG. (Keyword) Gastrectomy / Humans / Laparoscopy / Retrospective Studies / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12979 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34514719 ● Search Scopus @ Elsevier (PMID): 34514719 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12979 (DOI: 10.1111/ases.12979, PubMed: 34514719)
28.	Shohei Eto, Kouzou Yoshikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : Strategy for laparoscopic repair of inguinal hernia after robot-assisted radical prostatectomy., Asian Journal of Endoscopic Surgery, Vol.15, No.1, 155-161, 2022. (Summary) Robot-assisted radical prostatectomy (RARP) is nowadays being performed worldwide, and inguinal hernia (IH) continues to be a common complication of radical prostatectomy. Laparoscopic repair of IH is often difficult via internal dissection because of adhesion of the preperitoneal cavity. This study aimed to categorize the intraoperative condition of, and devise a strategy for, IH after RARP. Of 577 patients who underwent RARP, 18 developed IH. These 18 patients then underwent laparoscopic IH repair using the transabdominal preperitoneal approach (TAPP) or modified intraperitoneal onlay mesh repair (mIPOM). Internal dissection was categorized into two groups according to the appearance of Cooper's ligament (exposed or not exposed). After RARP, four patients had exposure of Cooper's ligament while 14 patients showed no exposure. Both patients in the exposed group underwent TAPP and all patients in the not-exposed group underwent mIPOM. There was no significant difference between normal TAPP and RARP regarding operative factors, and IH recurrence was not observed. Laparoscopic repair of IH after RARP is rendered safe and efficient by using our categorization based on the exposure of Cooper's ligament and extension of preperitoneal space. (Keyword) Hernia, Inguinal / Herniorrhaphy / Humans / Laparoscopy / Male / Prostatectomy / Robotics (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12985 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34514724 ● Search Scopus @ Elsevier (PMID): 34514724 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12985 (DOI: 10.1111/ases.12985, PubMed: 34514724)
29.	Chie Takasu, Emiko Kono, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : A "diversity and inclusion" lecture for promoting self-awareness among medical students., Surgery Today, Vol.52, No.6, 964-970, 2022. (Summary) The concept of 'diversity and inclusion' is being adopted worldwide, but it is not yet understood well in Japan. We conducted this study to evaluate the impact of a lecture aimed at increasing awareness of academic careers and the benefits of having diversity and inclusion. Two female surgeons delivered a 120-min lecture on "diversity and inclusion" to third-year medical students at Tokushima University. To assess the impact of the lecture, a questionnaire was distributed, for participants to complete anonymously before and after the lecture. Eighty-two students participated in the study (39 men, 38 women, and 5 unknown). Based on the questionnaire responses, 57.1% of the students had already perceived inequality in conduct because of gender. A comparison of pre- and post-lecture responses revealed a significant increase in confidence to succeed in their medical career (56.5% vs. 77.5%, p < 0.01). Learners were more likely to believe that gender would not become a barrier to career development (42.4% vs. 66.7%, p < 0.01). Moreover, 90.4% of the students felt positively about a career in surgery following the lecture. The lecture promoted awareness about diversity, self-awareness, and career development and motivated students to consider specializing in surgery later in their career. (Keyword) Career Choice / Female / Gender Identity / Humans / Japan / Male / Students, Medical / Surveys and Questionnaires (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02424-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35001195 ● Search Scopus @ Elsevier (PMID): 35001195 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02424-0 (DOI: 10.1007/s00595-021-02424-0, PubMed: 35001195)
30.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer., Annals of Surgical Oncology, Vol.29, No.6, 3887-3895, 2022. (Summary) Robotic gastrectomy (RG) has been rapidly adopted for gastric cancer (GC) treatment. However, the benefits of RG over laparoscopic gastrectomy (LG) for GC remain unclear. A total of 451 patients who underwent either RG (n = 83) or LG (n = 368) for GC were enrolled in this study. A 1:1 matched, propensity score-matched analysis was performed using the following factors: age, sex, body mass index, pT, pN, pStage, tumor location, vessel invasion, tumor markers, surgical procedure, reconstruction method, extent of lymphadenectomy, and Endoscopic Surgical Skill Qualification System qualified surgeon as an operator. The surgical outcomes of the two groups were compared. A well-balanced cohort of 158 patients was analyzed (n = 79 in the RG group, n = 79 in the LG group). Regarding the short-term outcomes, the respective blood loss volume, drain amylase content, and number of retrieved lymph nodes in the RG and LG groups were 38.62 ± 73.06 ml and 67.53 ± 108.20 ml (p < 0.05), 450 ± 371 IU/l and 1590 ± 6392 IU/l (p < 0.01), and 35.02 ± 15.51 and 25.28 ± 11.70 (p < 0.01). The morbidity rate was similar between the RG and LG groups (not significant [NS]). Regarding the long-term survival outcomes, there were no intergroup differences in 3-year overall survival (91.72% in the RG group vs. 83.39% in the LG group: NS) and 3-year, disease-free survival (93.31% in the vs. 90.44%: NS). RG was safe and contributed to better short-term outcomes and similar long-term survival outcomes compared with LG. (Keyword) Gastrectomy / Humans / Laparoscopy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-021-11203-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35006502 ● Search Scopus @ Elsevier (PMID): 35006502 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-021-11203-7 (DOI: 10.1245/s10434-021-11203-7, PubMed: 35006502)
31.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : Short-term outcomes of laparoscopic / robotic gastrectomy compared with open gastrectomy for advanced gastric cancer following chemotherapy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 261-265, 2022. (Summary) Purpose : This study aimed to investigate the short-term outcomes of laparoscopic gastrectomy / robotic gastrectomy after chemotherapy in patients with advanced gastric cancer and compare these outcomes with those of open gastrectomy. Methods : Fifty patients who underwent radical gastrectomy for advanced gastric cancer after chemotherapy between 2007 and 2021 were retrospectively analyzed. The patients were divided into two groups : the laparoscopic gastrectomy / robotic gastrectomy (n = 11) and open gastrectomy (n = 39) groups. The short-term outcomes of these procedures were subsequently examined. Results : The laparoscopic gastrectomy / robotic gastrectomy group had significantly shorter hospital stays and lower intraoperative blood loss than the open gastrectomy group. The overall complication rates were 12.8% (5 of 39 patients) and 0% (0 of 11 patients) in the open gastrectomy and laparoscopic gastrectomy / robotic gastrectomy groups, respectively (P = 0.1). Conclusions : Laparoscopic gastrectomy / robotic gastrectomy may be a surgical option after chemotherapy for patients with advanced gastric cancer. J. Med. Invest. 69 : 261-265, August, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 117728 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.261 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244778 ● Search Scopus @ Elsevier (PMID): 36244778 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.261 (Tokushima University Institutional Repository: 117728, DOI: 10.2152/jmi.69.261, PubMed: 36244778)
32.	Chie Takasu, Shoko Yamashita, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : The role of the immunoescape in colorectal cancer liver metastasis., PLoS ONE, Vol.16, No.11, e0259940, 2021. (Summary) The expression of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) indicate the efficacy of anti-PD-1/PD-L1 therapy in colorectal cancer (CRC), but are less useful for monitoring the efficacy of therapy of CRC liver metastasis (CRLM). This study investigated the effects of immune molecules on the prognosis of CRLM. We enrolled 71 patients with CRLM who underwent curative resection for CRC. We used immunohistochemistry to analyze the expression of PD-1, PD-L1, indoleamine-pyrrole 2,3-dioxygenase (IDO), and CD163 (a marker of tumor-associated macrophages [TAMs]) in metastatic tumors. The immune molecules PD-1, PD-L1, IDO, and TAMs were expressed in 32.3%, 47.8%, 45.0%, and 47.9% of metastatic CRC samples, respectively. The 5-year overall survival rates associated with immune molecule-positive groups were significantly better than in the negative groups (PD-1: 87.7% vs 53.2%, p = 0.023; PD-L1: 82.4% vs 42.3%, p = 0.007; IDO: 80.7% vs 43.5%, p = 0.007; TAMs: 82.6% vs 48.0%, p = 0.005). Multivariate analysis revealed PD-1 expression (p = 0.032, hazard ratio: 0.19), IDO expression (p = 0.049, hazard ratio: 0.37), and tumor differentiation (p<0.001, hazard ratio: 0.02) as independent prognostic indicators. PD-1 and TAMs in metastases were associated with less aggressive features such as smaller tumors. Furthermore, TAMs positively and significantly correlated with PD-1 expression (p = 0.011), PD-L1 expression (p = 0.024), and tended to correlate with IDO expression (p = 0.078). PD-1, PD-L1, IDO, and TAMs in CRLM were associated with less aggressive features and better prognosis of patients with CRC, indicating adaptive antitumor immunity vs immune tolerance. These molecules may therefore serve as prognostic markers for CRLM. (Keyword) Adaptive Immunity / Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, Differentiation, Myelomonocytic / B7-H1 Antigen / Biomarkers, Tumor / Colonic Neoplasms / Colorectal Neoplasms / Diagnostic Tests, Routine / Female / Gene Expression / Humans / Immune Tolerance / Indoleamine-Pyrrole 2,3,-Dioxygenase / Japan / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Metastasis / Prognosis / Programmed Cell Death 1 Receptor / Receptors, Cell Surface / Rectal Neoplasms / Transcriptome / Tumor-Associated Macrophages (Tokushima University Institutional Repository) ● Metadata: 117381 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0259940 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34797860 ● Search Scopus @ Elsevier (PMID): 34797860 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0259940 (Tokushima University Institutional Repository: 117381, DOI: 10.1371/journal.pone.0259940, PubMed: 34797860)
33.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto and Toshiaki Yoshimoto : Usefulness of Diagnostic Staging Laparoscopy for Advanced Gastric Cancer., The American Surgeon, 31348211038554, 2021. (Summary) For advanced gastric cancer (AGC), peritoneal metastasis is the most common determinant of unresectability, but accurate preoperative diagnosis for peritoneal metastasis is challenging. Staging laparoscopy (SL) can detect unsuspected peritoneal metastasis. This study retrospectively evaluated the utility of SL and its indication in patients with AGC. In this study, we enrolled 114 patients with pathologically diagnosed gastric adenocarcinoma who underwent SL. Of the 114 patients, 43 (37.7%) had peritoneal metastasis (P1 or CY1). Higher age, larger tumor size, type 4 GC, deeper tumor depth, elevated CA125, and ascites findings in preoperative CT were found to be significant predictors of peritoneal metastasis. In multivariate analysis, peritoneal metastasis was associated with type 4 GC (odds ratio [OR]: 6.11; 95% confidence interval [CI]: 1.87-19.8; P < .01) and ascites in CT (OR: 4.25; 95% CI: 1.48-12.1; P < .01). Staging laparoscopy is an effective tool to detect peritoneal metastasis from AGC. It can increase the curative resection rate and decrease unnecessary laparotomies. (Link to Publication Site) ● Publication site (DOI): 10.1177/00031348211038554 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34382447 ● Search Scopus @ Elsevier (PMID): 34382447 ● Search Scopus @ Elsevier (DOI): 10.1177/00031348211038554 (DOI: 10.1177/00031348211038554, PubMed: 34382447)
34.	Takuya Tokunaga, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : A Transabdominal Robotic Purse-String Suture Technique for Transanal Total Mesorectal Excision., Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A, Vol.31, No.8, 937-941, 2021. (Summary) Transanal total mesorectal excision (TaTME) is a novel technique that overcomes the problem of access to the deep pelvis during radical surgery for mid-rectal and lower rectal cancer. Although TaTME has several important steps, the creation of the distal purse-string suture following TaTME plays an important role in ensuring the integrity of the colorectal anastomosis. However, this procedure represents a major technical challenge for the surgeon. Robot-assisted surgery may make this suturing procedure easier than laparoscopic surgery because it permits intuitive wrist movements and a three-dimensional view. The aim of the present study was to investigate the usefulness of transabdominal robotic purse-string suture during anastomosis in TaTME. Twenty-seven patients, who underwent anastomosis using a single stapling technique (SST) during the TaTME of mid-rectal or lower rectal cancer, were enrolled in the study. The patients were allocated to two groups: 11 patients underwent transabdominal robotic purse-string suturing (the Robot group) and 16 patients underwent transanal purse-string suturing (the Transanal group). The characteristics and short-term surgical outcomes of the participants were compared between the two groups. The Robot group tended to have a shorter purse-string suturing time (541 206 seconds versus 729 310 seconds; = .07). Regarding the shape of the "donut" after SST anastomosis, in the Transanal group, 5 of the 16 participants had incomplete donuts with muscular defects and required additional suturing, whereas in the Robot group, all the participants had complete donuts ( = .04). Transabdominal robotic purse-string suturing may facilitate the suturing procedure and contribute to reliable anastomosis. (Keyword) Humans / Laparoscopy / Rectal Neoplasms / Rectum / Robotic Surgical Procedures / Robotics / Suture Techniques / Transanal Endoscopic Surgery (Link to Publication Site) ● Publication site (DOI): 10.1089/lap.2021.0286 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34242512 ● Search Scopus @ Elsevier (PMID): 34242512 ● Search Scopus @ Elsevier (DOI): 10.1089/lap.2021.0286 (DOI: 10.1089/lap.2021.0286, PubMed: 34242512)
35.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer., World Journal of Surgical Oncology, Vol.19, No.1, 201, 2021. (Summary) The lymphocyte to C-reactive protein (CRP) ratio (LCR) is an indicator of systemic inflammation and host-tumor cell interactions. The aim of this study was to investigate the prognostic significance of LCR in lower rectal cancer patients who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent CRT followed by curative surgery were enrolled in this study. Routine blood examinations were performed before and after CRT were used to calculate pre-CRT LCR and post-CRT LCR. The median LCR was used to stratify patients into low and high LCR groups for analysis. The correlation between pre- and post-CRT LCR and clinical outcomes was retrospectively investigated. The pre-CRT LCR was significantly higher than the post-CRT LCR (11,765 and 6780, respectively, P < 0.05). The 5-year overall survival rate was significantly higher for patients with high post-CRT LCR compared with low post-CRT LCR (90.6% and 65.5%, respectively, P < 0.05). In univariate analysis, post-CRT LCR, post-CRT neutrophil to lymphocyte ratio, and fStage were significant prognostic factors for overall survival. In multivariate analysis, post-CRT LCR, but not other clinicopathological factors or prognostic indexes, was a significant prognostic factor for overall survival (P < 0.05). Post-CRT LCR could be a prognostic biomarker for patients with lower rectal cancer. (Keyword) C-Reactive Protein / Chemoradiotherapy / Humans / Lymphocytes / Neoplasm Staging / Prognosis / Rectal Neoplasms / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117394 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02319-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34229704 ● Search Scopus @ Elsevier (PMID): 34229704 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02319-x (Tokushima University Institutional Repository: 117394, DOI: 10.1186/s12957-021-02319-x, PubMed: 34229704)
36.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : The influence and countermeasure of obesity in laparoscopic colorectal resection., Annals of Gastroenterological Surgery, Vol.5, No.5, 677-682, 2021. (Summary) The aim of this study was to investigate the influence of obesity and the usefulness of a preoperative weight loss program (PWLP) for obese patients undergoing laparoscopic colorectal resection (LCR). Study 1: 392 patients who underwent LCR for colorectal cancer were divided into two groups: those with a body mass index (BMI) ·25 kg/m (n = 113) and those with a BMI <25 kg/m (n = 279). The influence of BMI on LCR was investigated. Study 2: Patients with a BMI ·28 kg/m who were scheduled to undergo LCR (n = 7, mean body weight 87.0 kg, mean BMI 33.9 kg/m) undertook a PWLP including caloric restriction and exercise for 29.6 (15-70) days. The effects of this program were evaluated. Study 1: The BMI ·25 kg/m group had a prolongation of operation time and hospital stay than the BMI <25 kg/m group. Study 2: The patients achieved a mean weight loss of 6.9% (-6.0 kg). The mean visceral fat area was significantly decreased by 18.0%, whereas the skeletal muscle mass was unaffected. The PWLP group had a significantly lower prevalence of postoperative complications compared with the BMI ·25 kg/m group. Obesity affected the surgical outcomes in LCR. A PWLP may be useful for obese patients undergoing LCR. (Tokushima University Institutional Repository) ● Metadata: 117274 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12455 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585052 ● Search Scopus @ Elsevier (PMID): 34585052 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12455 (Tokushima University Institutional Repository: 117274, DOI: 10.1002/ags3.12455, PubMed: 34585052)
37.	Chie Takasu, Katsuki Miyazaki, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto, Hirohisa Ogawa, Yuji Morine and Mitsuo Shimada : Effect of TU-100 on Peyer's patches in a bacterial translocation rat model., Annals of Gastroenterological Surgery, Vol.5, No.5, 683-691, 2021. (Summary) Daikenchuto (TU-100), a Japanese herbal medicine, is widely used for various gastrointestinal diseases. We have previously reported that TU-100 suppresses CPT-11-induced bacterial translocation (BT) by maintaining the diversity of the microbiome. In this study we show that TU-100 modulates the immune response during BT by inducing PD-1 expression in Peyer's patches. Eighteen male Wistar rats were divided into four groups: a control group; a control + TU-100 group, given TU-100 1000 mg/kg orally for 5 d; a BT group, given CPT-11 250 mg/kg intra-peritoneal for 2 d; and a TU-100 group, given TU-100 1000 mg/kg orally for 5 d with CPT-11 250 mg/kg intra-peritoneal on days 4 and 5. The size of Peyer's patch was significantly bigger in the BT group compared to the control group (9.0 104 m vs 29.4 104 m, < .05), but improved in the TU-100 group (15.4 104 m, < .005). TU-100 significantly induced PD-1 expression in Peyer's patch compared to the control group and the BT group (control vs BT vs TU-100 = 4.3 4.9 vs 5.1 10.3 vs 17.9 17.8). The CD4 cells were increased in the BT group ( < .05) compared to the control group but decreased in the TU-100 group. The Foxp3 cells were increased in the BT group compared to the control group ( < .05), and further increased in the TU-100 group compared to the BT group. CPT-11 significantly increased TLR4, NF- , TNF- mRNA expressions in the BT group. TU-100 cotreatment significantly reversed these mRNA expressions. TU-100 may have a protective effect against BT through PD-1 expression in Peyer's patch. (Tokushima University Institutional Repository) ● Metadata: 117275 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12460 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585053 ● Search Scopus @ Elsevier (PMID): 34585053 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12460 (Tokushima University Institutional Repository: 117275, DOI: 10.1002/ags3.12460, PubMed: 34585053)
38.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Chiharu Nakasu and Mitsuo Shimada : Robotic-assisted total gastrectomy in a patient with gastric cancer associated with situs inversus totalis: With video., Asian Journal of Endoscopic Surgery, Vol.14, No.2, 297-300, 2021. (Summary) Situs inversus totalis (SIT) refers to an inverted position of the major visceral organ as a "mirror image" of the regular location. We present a video of a robotic-assisted total gastrectomy in a 84-year-old man with SIT. The patient was diagnosed with advanced gastric cancer in the U region. The port placement was done as mirror images of our usual settings. Lymph node dissection was performed with a completely reverse approach to the usual procedure. After total gastrectomy, an intracorporal esophagojejunostomy was performed by circular method. All procedures were performed safely with no intraoperative complications and the patient was discharged uneventfully. Pathological diagnosis confirmed moderately differentiated adenocarcinoma and the depth of invasion was to the subserosa; there were five metastatic lymph nodes. In patients who have gastric cancer with SIT, a robotic-assisted total gastrectomy can be performed safely without surgical complication. Robots are useful for performing a total gastrectomy in SIT. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12860 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32875706 ● Search Scopus @ Elsevier (PMID): 32875706 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12860 (DOI: 10.1111/ases.12860, PubMed: 32875706)
39.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Pre-operative Weight Loss Program for Obese Patients Undergoing Laparoscopic Gastrectomy., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 165-169, 2021. (Summary) Background : The aim of this study was to investigate the influence of obesity and the usefulness of a pre-operative weight loss program (PWLP) for obese patients undergoing laparoscopic gastrectomy (LG) for gastric cancer (GC). Materials and Methods : Study1 : 219 patients who underwent laparoscopic distal gastrectomy (LDG) for GC were divided into 2 groups : body mass index (BMI) 28 and BMI < 28kg /2. The influence of BMI in LG surgery was investigated. Study2 : The BMI 28 kg /2 patients with a planned LG (n = 8) undertook a PWLP including calorie restriction and exercise. The effects of this program were evaluated. Results : Study1 : The BMI 28kg /2 group showed significantly longer operation times, more blood loss and a higher frequency of post-operative complications than that of the BMI < 28kg /2 group. Study 2 : The patients achieved a weight loss of 4.2%. The visceral fat area (VFA) was significantly decreased by 10.6%, whereas skeletal muscle mass was unaffected. The PWLP group showed shorter operation times, less blood loss and a lower frequency of post-operative complications compared with that of the BMI 28kg /2 group. Conclusion : Obesity is an important risk factor and a pre-operative weight loss program is useful for obese patients undergoing a LG. J. Med. Invest. 68 : 165-169, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 116007 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.165 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994464 ● Search Scopus @ Elsevier (PMID): 33994464 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.165 (Tokushima University Institutional Repository: 116007, DOI: 10.2152/jmi.68.165, PubMed: 33994464)
40.	Jun Higashijima, Takuya Tokunaga, Toshiaki Yoshimoto, Shohei Eto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Hiroshi Okitsu, Masashi Ishikawa, Hidenori Miyake, Toshiyuki Yagi, Toru Kono and Mitsuo Shimada : A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer., International Journal of Clinical Oncology, Vol.26, No.5, 875-882, 2021. (Summary) We clarified the safety and efficacy of preoperative chemoradiotherapy for locally advanced rectal cancer using a multidrug regimen (S-1 +xaliplatin +evacizumab). This multicenter phase II trial involved 47 patients with locally advanced rectal cancer. All patients received S-1 orally (80 mg/m/day on days 1-5, 8-12, 15-19, and 22-26) and infusions of oxaliplatin (50 mg/m on days 1, 8, 15, and 22) and bevacizumab (5 mg/kg on days 1 and 15). The total radiation dose was 40 Gy delivered in daily fractions of 2 Gy via the four-field technique. The primary endpoint was the pathological complete response rate. The secondary endpoints were safety (incidence of adverse events) and clinical response, relapse-free survival, overall survival, local recurrence, R0 resection, downstaging, and treatment completion rates. All 47 patients received chemoradiotherapy, and 44 patients underwent curative resection. Two patients refused surgery and selected a watch-and-wait strategy. The pathological complete response rate was 18.2% in patients who underwent curative resection. The clinical response rate was 91.3% in 46 patients. Concerning hematotoxicity, there was one grade 4 adverse event (2.1%) and seven grade 3 events (14.9%). Diarrhea was the most frequent non-hematotoxic event, and the grade 3 event rate was 25.5%. Although preoperative chemoradiotherapy for patients with locally advanced rectal cancer using the S-1 +xaliplatin +evacizumab regimen did not achieve the expected pathological complete response rate, this regimen led to an improved clinical response rate. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-01868-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33486623 ● Search Scopus @ Elsevier (PMID): 33486623 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-01868-1 (DOI: 10.1007/s10147-021-01868-1, PubMed: 33486623)
41.	Shoko Yamashita, Masaaki Nishi, Tetsuya Ikemoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery., Surgery Today, Vol.51, No.6, 1022-1027, 2021. (Summary) Venous thromboembolism (VTE) is a major complication after abdominal surgery; however, the best strategy for preventing VTE after surgery is not yet established. We performed this study to investigate the incidence of perioperative VTE and evaluate the efficacy of a VTE preventive strategy for patients undergoing surgery for colorectal cancer (CRC). The subjects of this retrospective analysis were 228 patients who underwent curative surgical resection for CRC between 2012 and 2016. The patients were treated with thromboprophylaxis including enoxaparin. We assessed the perioperative VTE occurrence rate and investigated the risk factors for postoperative VTE. Among the 228 patients, 77 had a preoperative D-dimer level of > 1.0 g/mL and 12 had deep vein thrombosis (DVT) diagnosed by ultrasonography preoperatively. Of the remaining 216 patients, short-term VTE (< 30 days) developed in two patients (0.9%) and long-term VTE (30 days-3 years) developed in seven (3.2%). The mortality rate of patients with VTE was 0%. The univariate analysis indicated that pulmonary disease was the risk factor for short-term VTE, whereas obesity, hyperlipidemia, and a preoperative history of pulmonary embolism were the risk factors for long-term VTE (p < 0.05). The findings of this analysis show that our preventive protocol including enoxaparin is an effective strategy for preventing postoperative VTE. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-020-02201-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33387025 ● Search Scopus @ Elsevier (PMID): 33387025 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-020-02201-5 (DOI: 10.1007/s00595-020-02201-5, PubMed: 33387025)
42.	Shohei Okikawa, Jun Higashijima, Masaaki Nishi, Toshiaki Yoshimoto, Shohei Eto, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : SDF-1 expression after preoperative chemoradiotherapy is associated with prognosis in patients with advanced lower rectal cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 309-314, 2021. (Summary) Stromal cell-derived factor-1 (SDF-1) expression is associated with cancer progression, as a biomarker of prognosis. We clarified the significance of SDF-1 expression on chemoradiotherapy (CRT) resistance and prognosis in advanced lower rectal cancer patients. We evaluated 98 patients with advanced lower rectal cancer who underwent preoperative CRT. All patients received 40 Gy of radiation therapy, with concurrent chemotherapy containing fluorinated pyrimidines, followed by surgical resection. SDF-1 expression in surgical specimens was examined by immunohistochemistry. We divided the patients into SDF-1-positive- (n = 52) and SDF-1-negative groups (n = 46) and compared the clinicopathological factors and survival rates. The SDF-1-positive group was more resistant to CRT than the SDF-1-negative group (non-responder rate, 63.5% vs. 47.8%, respectively ; p = 0.12). Overall survival (OS) in the SDF-1 positive group was significantly poorer vs. the SDF-1-negative group (5-year OS, 73.4% vs. 88.0%, respectively ; p = 0.02), and disease-free survival (DFS) was worse (5-year DFS, 61.0% vs. 74.1%, respectively ; p = 0.07). Multivariate analysis confirmed that SDF-1 expression was a significant independent prognostic predictor of OS (p = 0.04). SDF-1 expression after preoperative CRT is significantly associated with a poor prognosis in advanced lower rectal cancer patients and is a promising biomarker. J. Med. Invest. 68 : 309-314, August, 2021. (Keyword) Chemoradiotherapy / Disease-Free Survival / Humans / Neoplasm Staging / Prognosis / Rectal Neoplasms / Rectum (Tokushima University Institutional Repository) ● Metadata: 116500 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.309 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759150 ● Search Scopus @ Elsevier (PMID): 34759150 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.309 (Tokushima University Institutional Repository: 116500, DOI: 10.2152/jmi.68.309, PubMed: 34759150)
43.	Shohei Eto, Kouzou Yoshikawa, Yukako Takehara, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : Usefulness of a multidisciplinary surgical site infection team in colorectal surgery., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 256-259, 2021. (Summary) Background : Surgical site infection (SSI) is an adverse event that places a major burden on patients and staff. In this study, we examined the occurrence of SSI and the characteristics of patients referred to the SSI team after colorectal surgery. Methods : In total, 955 patients underwent colorectal surgery at our hospital from 2014 to 2019. Of these 955 patients, 516 received therapeutic support by the SSI team from 2017 to 2019. All patients were evaluated using an SSI surveillance sheet, and we checked for reports of SSI once a month. Each attending physician performed SSI prophylaxis (use of new instruments before wound irrigation and closure). Results : SSI occurred in 80 (8.4%) patients. The incidence of SSI and the incidence of surface SSI were higher in the patients who did not receive intervention by the SSI team than in the patients who did. Organ /pace SSI occurred in 18 patients. Among patients with surface SSI, Enterococcus was the most commonly detected bacteria. Among the 18 patients with organ /pace SSI, 5 developed anastomotic leakage and 4 developed intra-abdominal abscesses. Conclusions : An SSI team for prevention and treatment of infection may contribute to reduction of SSI. J. Med. Invest. 68 : 256-259, August, 2021. (Keyword) Colorectal Surgery / Humans / Incidence / Risk Factors / Surgical Wound Infection / Therapeutic Irrigation (Tokushima University Institutional Repository) ● Metadata: 116491 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.256 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759140 ● Search Scopus @ Elsevier (PMID): 34759140 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.256 (Tokushima University Institutional Repository: 116491, DOI: 10.2152/jmi.68.256, PubMed: 34759140)
44.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 362-367, 2021. (Summary) Background : CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) is the master regulator of programmed cell death-ligand 1 (PD-L1). We aimed to clarify the significance of CMTM6 expression in gastric cancer (GC). Methods : A total of 105 patients who had undergone curative surgical resection for stage II /II GC at Tokushima University Hospital were included in this study. The expression of CMTM6 was examined by immunohistochemistry. Additionally, the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. Results : CMTM6 was not positively correlated with any of the factors examined. The overall survival (OS) rates were significantly poorer in the CMTM6 high-expression group than in the CMTM low-expression group (5-year OS : 57.2% vs. 79.2%, respectively ; p < 0.05). Disease-free survival (DFS) was significantly poorer in the CMTM high-expression group than in the CMTM6 low-expression group (5-year DFS : 52.8% vs. 72.4%, respectively ; p < 0.05). Multivariate analysis confirmed CMTM6 expression as an independent prognostic factor in DFS (p < 0.05). CMTM6 expression tended to be correlated with PD-L1 expression (p = 0.07). Conclusions : CMTM6 is associated with a poor prognosis and immunotolerance through PD-L1 in GC. J. Med. Invest. 68 : 362-367, August, 2021. (Keyword) B7-H1 Antigen / Chemokines / Humans / MARVEL Domain-Containing Proteins / Myelin Proteins / Prognosis / Stomach Neoplasms / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 116552 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.362 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759159 ● Search Scopus @ Elsevier (PMID): 34759159 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.362 (Tokushima University Institutional Repository: 116552, DOI: 10.2152/jmi.68.362, PubMed: 34759159)
45.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto and Toshiaki Yoshimoto : Transoral Anvil Delivery System With Tension-Free Method for Esophagojejunostomy After Laparoscopic Total Gastrectomy Prevents The Postoperative Stenosis., The American Surgeon, 3134820973393, 2020. (Link to Publication Site) ● Publication site (DOI): 10.1177/0003134820973393 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33307725 ● Search Scopus @ Elsevier (PMID): 33307725 ● Search Scopus @ Elsevier (DOI): 10.1177/0003134820973393 (DOI: 10.1177/0003134820973393, PubMed: 33307725)
46.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Impact of sidedness of colorectal cancer on tumor immunity., PLoS ONE, Vol.15, No.10, e0240408, 2020. (Summary) Clinical and molecular characteristics differ between right-sided and left-sided colorectal cancer (CRC). This study aimed to clarify the correlation between CRC sidedness and tumor immunity. A total of 102 patients who underwent curative colectomy for stage II/III CRC were included in this study. The expression of programmed cell death (PD)-1, PD1-ligand 1 (PD-L1), forkhead box P3 (Foxp3), transforming growth factor (TGF)-β, and indoleamine-pyrrole 2,3-dioxygenase (IDO) were examined using immunohistochemistry and the relationships between sidedness and several prognostic factors were examined. Clinicopathological factors were not significantly different between right- and left-sided CRC. The tumor immunity-related molecule PD-L1 was more highly expressed in right-sided than in left-sided CRC (62.9% vs. 30.6%, p<0.01). No significant difference was found in overall survival (OS) and disease-free survival (DFS) by sidedness. PD-1 and Foxp3 expression were significant prognostic factors for OS. Lymph node metastasis (N), lymphatic invasion (ly), and PD-L1 expression were significant prognostic factors for DFS. In right-sided CRC, IDO-positive patients had a poor OS (p<0.05), and IDO was the only independent prognostic indicator for OS. N and venous invasion were identified as independent prognostic indicators for DFS. In left-sided CRC, univariate analysis identified PD-1, PD-L1, and Foxp3 expression as significant predictors of poor OS. Multivariate analysis confirmed PD-L1 expression as an independent prognostic indicator. N, ly, and PD-L1 expression levels were identified as significant predictors of poor DFS. The prognostic factors were IDO in right-sided CRC and PD-L1 and Foxp3 in left-sided CRC. These findings indicated that tumor immunity might play different roles depending upon sidedness. Tumor location may be an important factor to consider when assessing immune response and therapeutic decisions in CRC patients. (Keyword) Adult / Aged / Aged, 80 and over / B7-H1 Antigen / Biomarkers, Tumor / Colorectal Neoplasms / Disease-Free Survival / Female / Forkhead Transcription Factors / Gene Expression Regulation, Neoplastic / Humans / Indoleamine-Pyrrole 2,3,-Dioxygenase / Male / Middle Aged / Neoplasm Staging / Prognosis / Programmed Cell Death 1 Receptor / Transforming Growth Factor beta / Up-Regulation (Tokushima University Institutional Repository) ● Metadata: 115400 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0240408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33045001 ● Search Scopus @ Elsevier (PMID): 33045001 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0240408 (Tokushima University Institutional Repository: 115400, DOI: 10.1371/journal.pone.0240408, PubMed: 33045001)
47.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Trans-abdominal Pre-peritoneal (TAPP) Inguinal Hernia Repair with Liquid-injection and Gauze Dissection., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 271-273, 2020. (Summary) Purpose : This report describes a novel technique for trans-abdominal pre-peritoneal (TAPP) inguinal hernia repair using liquid injection and gauze dissection. Methods : Twenty-five cases underwent TAPP inguinal hernia repair with liquid-injection and gauze dissection. Before the initial peritoneal incision, liquid injection was performed percutaneously into the pre-peritoneal space at the outside of the internal inguinal ring and the inside of the seminal duct. Especially, at the inside of the seminal duct, the liquid was injected into the space between the superficial and deep lobe of pre-peritoneal fascia. Gauze was effectively used to dissect this liquid-injected space. Results : In comparison with the cases of inguinal hernia repair without liquid-injection and gauze dissection, the cases who underwent TAPP inguinal hernia repair with liquid-injection and gauze dissection experienced shorter operation times and no complications or recurrence. Conclusions : TAPP inguinal hernia repair with liquid-injection and gauze dissection appears to be a safe and feasible procedure. J. Med. Invest. 67 : 271-273, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115423 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.271 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148900 ● Search Scopus @ Elsevier (PMID): 33148900 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.271 (Tokushima University Institutional Repository: 115423, DOI: 10.2152/jmi.67.271, PubMed: 33148900)
48.	Yukako Takehara, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Desmoid-type fibromatosis difficult to distinguish from GIST : A case report., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 375-377, 2020. (Summary) Background : Desmoid-type fibromatosis is a very rare disease that has no characteristic image findings, so it is often difficult to differentiate from gastrointestinal stromal tumor (GIST). A case of desmoid-type fibromatosis that was difficult to differentiate from GIST is reported. The decisive factor in the diagnosis was positive nuclear immunostaining for β-catenin nucleus. Case presentation : A man is his 30s had no significant past medical history, including no abdominal surgery. A medical check-up found a large tumor in the right lateral abdomen. After some examinations, a preoperative diagnosis of GIST was made, and open ileocecal resection was performed. However, the final diagnosis based on the pathological findings was desmoid-type fibromatosis. Conclusions : We should consider desmoid-type fibromatosis when we find a large abdominal mass, but it may be difficult to diagnose based only on imaging findings. Immunohistochemical examination of the specimen may make the diagnosis. J. Med. Invest. 67 : 375-377, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115460 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.375 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148921 ● Search Scopus @ Elsevier (PMID): 33148921 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.375 (Tokushima University Institutional Repository: 115460, DOI: 10.2152/jmi.67.375, PubMed: 33148921)
49.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : Impact of using a perioperative artificial endocrine pancreas in pancreatic resection., Annals of Gastroenterological Surgery, Vol.4, No.5, 591-596, 2020. (Summary) Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose levels. We investigated whether using an artificial pancreas perioperatively to provide appropriate blood glucose control could reduce postoperative complications following pancreatectomy. We retrospectively enrolled 52 patients who underwent pancreatectomy at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 patients received perioperative blood glucose control using an artificial pancreas. Postoperative blood glucose control with manual insulin injections based on a sliding scale was performed in the earlier 26 patients (controls). We compared surgical outcomes between the artificial pancreas group and the control group. There was no significant difference in patients' white blood cell or neutrophil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were higher in the artificial pancreas group. The number of serious complications of Clavien-Dindo grade >IIIa was significantly lower in the artificial pancreas group ( < .05). Using an artificial pancreas for perioperative blood glucose control in patients undergoing pancreatectomy decreased the number of serious complications through proper management of blood glucose levels without hypoglycemia, and may influence peripheral lymphocytes. (Tokushima University Institutional Repository) ● Metadata: 116476 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12374 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33005854 ● Search Scopus @ Elsevier (PMID): 33005854 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12374 (Tokushima University Institutional Repository: 116476, DOI: 10.1002/ags3.12374, PubMed: 33005854)
50.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Usefulness of virtual three-dimensional image analysis in inguinal hernia as an educational tool., Surgical Endoscopy, Vol.34, No.2, 1923-1928, 2020. (Summary) The pre-operative three-dimensional (3D) imaging technique has resulted in a better surgical outcome for patients and has been used as an education and diagnostic tool. However, there are no reports concerning the usefulness of the 3D imaging technique in laparoscopic transabdominal pre-peritoneal repair (TAPP) so the aim of this study was to investigate the usefulness of the 3D imaging technique in laparoscopic TAPP as an educational tool for medical students. Six (6) patients who underwent laparoscopic TAPP for inguinal hernia were enrolled in this study. 3D reconstruction was performed from pre-operative computed tomography (CT) and the usefulness of pre-operative 3D simulation compared with intra-operative laparoscopic imaging was validated. Moreover, thirty (30) medical students at the university completed a multiple-choice questionnaire (MCQ) to determine the level of their satisfaction and understanding of anatomy resulting from the study. The local anatomy of the patients was identified as the same during the operation as the pre-operative 3D simulation. The results of the MCQ showed that most of the medical students were extremely (23%) or very (67%) satisfied with the effect of pre-operative 3D simulation on the quality of the surgery. Moreover, most students could understand the surgery anatomy by the 3D simulation extremely well (40%) or very well (47%) and agreed on the usefulness of this procedure for learning anatomy. Pre-operative 3D simulation increases the understanding of detailed anatomy and virtual three-dimensional image analysis in laparoscopic TAPP is useful as an educational tool for medical students. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-019-06964-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31312962 ● Search Scopus @ Elsevier (PMID): 31312962 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-019-06964-y (DOI: 10.1007/s00464-019-06964-y, PubMed: 31312962)
51.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 【最先端医療を支える病理学】消化管最新外科手術における病理の役割, Shikoku Acta Medica, Vol.76, No.1-2, 3-8, 2020. (Keyword) 胃腫瘍(外科的療法,病理学) 細胞診術中期生活の質直腸腫瘍(外科的療法) 保険適用範囲 *ロボット手術ヒト (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050566774761702016 (CiNii: 1050566774761702016)
52.	Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Koichi Tsuneyama and Mitsuo Shimada : Two cases of non-mucinous cystadenomas of the pancreas with pancreatobiliary phenotype and ovarian-like stroma., Surgical Case Reports, Vol.5, No.1, 117, 2019. (Summary) Diagnosis of cystic tumor of the pancreas is based on the World Health Organization criteria that classify pancreatic cystadenomas into four types: intra-ductal papillary mucinous neoplasms, mucinous cystic neoplasms (MCNs), serous cystic neoplasms, and solid pseudo-papillary neoplasms depending on their secretion and presence of ovarian-like stroma. Recently, Albores-Saavedra identified non-mucinous cystadenomas of the pancreas with pancreato-biliary phenotype and ovarian-like stroma. This precipitated examination of the proportions of these rare tumors in patients treated at Tokushima University Hospital. Case 1 was a 40-year-old woman with a cystic tumor in the tail of the pancreas. Computed tomography (CT) revealed a diffuse and non-enhanced cystic tumor in the tail of the pancreas. This tumor was diagnosed as a simple cyst at this point. However, 2ears later, the tumor had increased in size by 3m. Thus, laparoscopic distal pancreatectomy was performed. The content of the cyst was serous. The epithelial cells were lined with a single layer of cuboidal cells and the tumor had ovarian-like stroma pathologically. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. In Case 2, a cystic tumor in the pancreas was found by medical examination in a woman in her sixties who presented without symptoms. CT showed a 1.5-cm cystic tumor in the tail and body of the pancreas and a septum in the cyst. Nine years later, the tumor had grown to 2.4m in diameter and had a clear septum in the cyst. This tumor was diagnosed preoperatively as MCN. Thus, laparoscopic distal pancreatectomy was performed. The cyst contained serous fluid. Microscopic examination showed no ovarian-like stroma and the epithelial cells were lined by a single layer of cuboidal cells. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. Accurate preoperative diagnosis of this type of pancreatic cystic tumor may be difficult, although it occurs more often than expected. Non-mucinous cystadenomas of the pancreas with ovarian-like stroma need to be considered as a differential diagnosis. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0673-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31338648 ● Search Scopus @ Elsevier (PMID): 31338648 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0673-y (DOI: 10.1186/s40792-019-0673-y, PubMed: 31338648)
53.	Shoko Iwahashi, Masaaki Nishi, Toshiaki Yoshimoto, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Yuuma Wada, Yoshimi Bando and Mitsuo Shimada : A case of gastric heterotopic pancreas with gastroduodenal invagination., Surgical Case Reports, Vol.5, No.1, 110, 2019. (Summary) Heterotopic pancreas (HP) is a rare disease commonly found incidentally on imaging studies, at endoscopy or at autopsy and can be associated with abdominal pain, vomiting, heart burn, gastric outlet obstruction, and even dysphagia in very rare cases. Heinrich's classified HP into three groups, types1-3, with Heinrich's type 3 HP the rarest and difficult to diagnose properly because it has only pancreatic ducts but has no islet and acini. The aim of this study is to report a case of gastric outlet obstruction caused by type 3 HP with gastroduodenal invagination with reference to the literature and diagnosed finally by immuno-histochemical analysis. The case presented is a 40-year-old male presenting with vomiting and abdominal pain. Computed tomography (CT) revealed a cystic mass in the upper abdomen and he was referred to the Tokushima University. Gastric fiber showed that the pedunculated mass originated from the stomach. An open distal gastrectomy was performed. Pathologically, there was small glands proliferation in the sub-mucosal (SM) layer which was membrane and cytoplasm (MUC)1 positive and muscle proliferation. This finding revealed the tumor as HP. Postoperative course was uneventful and the patient was discharged 12 days after surgery. The patient has remained well 12 months after surgery. HP should be considered in the differential diagnosis of SM tumors with gastroduodenal invagination even if this is a rare symptom. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0669-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31292813 ● Search Scopus @ Elsevier (PMID): 31292813 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0669-7 (DOI: 10.1186/s40792-019-0669-7, PubMed: 31292813)
54.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (Summary) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 113041 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0210579 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (Tokushima University Institutional Repository: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
55.	Toshiaki Yoshimoto, Yuji Morine, Chie Takasu, Rui Feng, Tetsuya Ikemoto, Kouzou Yoshikawa, Shuichi Iwahashi, Yu Saitou, Hideya Kashihara, Masatake Akutagawa, Takahiro Emoto, Yosuke Kinouchi and Mitsuo Shimada : Blue light-emitting diodes induce autophagy in colon cancer cells by Opsin 3., Annals of Gastroenterological Surgery, Vol.2, No.2, 154-161, 2018. (Summary) Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro. Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G G-protein inhibitor NF023 in these assays. Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment. Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor. (Tokushima University Institutional Repository) ● Metadata: 113689 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12055 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29863164 ● Search Scopus @ Elsevier (PMID): 29863164 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12055 (Tokushima University Institutional Repository: 113689, DOI: 10.1002/ags3.12055, PubMed: 29863164)
56.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
57.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)

Review, Commentary:

1.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (Summary) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)

Proceeding of International Conference:

1.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Circulating exosomal microRNA signature to predict peritoneal metastasis in patients with advanced gastric cancer., ASCO-GI, San Francisco, Jan. 2024.
2.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Immunoscore and Frailty in Colorectal Cancer, IASGO-CME Advanced Post-Graduate Course in Kobe 2023, Kobe, Nov. 2023.
3.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : The impact of preoperative neutrophil-lymphocyte ratio as the predictive marker of postoperative weight loss and improving diabetes in sleeve gastrectomy., SAGES 2020, クリーブランド, Aug. 2020.
4.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefuluness of the OrVil method in LATG, SAGES 2020, クリーブランド, Aug. 2020.
5.	Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Mitsuo Shimada : The Usefulness of Intraoperative X-ray Fluoroscopy for Avoiding Urethral Injury in Transperineal total Mesorectal Excision, IASGO2019, Bangkok, Oct. 2019.
6.	Toshiaki Yoshimoto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : The tumor suppressive effects of blue LED via Opn3 in colon cancer, 第10回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2019.
7.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of the orVil method in LATG, 第10回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2019.
8.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of our step-wise training system for robotic assisted gastrectomy, SAGES 2019, Baltimore, Apr. 2019.
9.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Masaaki Nishi and Chie Takasu : Prognostic Prediction of Mass-Forming Intrahepatic Cholangiocarcinoma from Diffusion Weighted Image of Magnetic Resonance Image, SSO's 72nd Annual Cancer Symposium, San Diego, Mar. 2019.
10.	Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : Transanal total mesorectal excision for rectal cancer, 第9回日本・モンゴル国際消化器癌シンポジウム, Aug. 2018.
11.	Toshiaki Yoshimoto, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Sorafenib therapy combined with surgical resection or TACE, APASL STC2018, Yokohama, May 2018.
12.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative Prognostic Nutritional Index Predicts Both Short-and Long-Term Outcomes after Liver Resection For Hepatocellular Carcinoma, AMERICAN COLLEGE OF SURGEONS 2017(ACS), San Diego, Oct. 2017.
13.	Rui Feng, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Kouzou Yoshikawa, Toshiaki Yoshimoto and Jun Higashijima : The impact of red LED irradiation on hepatocytes preservation, 18th Congress of the European Society for Organ Transplantation(ESOT)2017, Barcelona, Aug. 2017.
14.	Mitsuo Shimada, Rui Feng, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto and Jun Higashijima : A new 2-step protocol for human adipose derived mesenchymal stem cell differentiation to insulin-producing cells using xeno-antigen free reagents, 18th Congress of the European Society for Organ Transplantation(ESOT), Barcelona, Aug. 2017.
15.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
16.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : Feasibility of laparoscopic gastrectomy for elderly patients., SAGES, Houston, Mar. 2017.
17.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
18.	Daichi Ishikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Yuji Morine, Satoru Imura and Mitsuo Shimada : Signigficance of CD4+CD49b+regulatory T cells and Foxp3+regulatory T cells in the peripheral blood of cancer patients, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
19.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Atsushi Takata and Mitsuo Shimada : Ki-67 and Survivin Expressions as Predictive Factors in the Rectal Cancer Treated with Preoperative CRT, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
20.	Atsushi Takata, Jun Higashijima, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : The influence of circular muscle incision on intestinal peristalsis and anastomosis, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
21.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : Recurrent feature after radiofrequency ablation therapy for hepatocellular carcinoma, 4th International Conference of FACO, 廈門, Sep. 2016.
22.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
23.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Atsushi Takata and Mitsuo Shimada : The usefulness of Ki-67 and survivin expressions as predictive factors for the rectal cancer with preoperative CRT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
24.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
25.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Kouzou Yoshikawa and Toshiaki Yoshimoto : The correlation between serum CA19-9 level and the epigenetic alteration in intrahepatic cholangiocarcinoma., IASGO Advanced Post-Graduate Course in Sendai 2016, Sendai, Apr. 2016.

Proceeding of Domestic Conference:

1.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種予測におけるエクソソームmiRNAの有用性, 第96回日本胃癌学会総会, Feb. 2024.
2.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第96回日本胃癌学会総会, Feb. 2024.
3.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対する経裂孔ロボット支援手術, 第96回日本胃癌学会総会, Feb. 2024.
4.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The ingenuity of robotic surgery for advanced gastric cancer, 第96回日本胃癌学会総会, Feb. 2024.
5.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いての胃癌腹膜播種の予測, 第56回制癌剤適応研究会, Feb. 2024.
6.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
7.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後の鼠径ヘルニアに対する腹腔鏡下ヘルニア修復術についての検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
8.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術におけるトレーニングプログラムの確立, 第36回日本内視鏡外科学会総会, Dec. 2023.
9.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対する経肛門的側方リンパ節郭清の手術手技と短期成績の検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
10.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第36回日本内視鏡外科学会総会, Dec. 2023.
11.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 非アルコール性脂肪肝炎に対する減量・代謝改善手術の意義, 第36回日本内視鏡外科学会総会, Dec. 2023.
12.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔アプローチ)の有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
13.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
14.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第36回日本内視鏡外科学会総会, Dec. 2023.
15.	Toshiaki Yoshimoto, Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 再発直腸癌に対する経肛門アプローチにおけるホログラムの有用性, 第32回日本コンピュータ外科学会大会, Dec. 2023.
16.	Yuuma Wada, Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
17.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 青色LEDはmetabolic couplingを抑制することで抗腫瘍効果をもたらす, 第34回日本消化器癌発生学会総会, Nov. 2023.
18.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 胃癌腹膜播種診断マーカーの臨床的有用性, 第34回日本消化器癌発生学会総会, Nov. 2023.
19.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとフレイルの予後に与える影響, 第34回日本消化器癌発生学会総会, Nov. 2023.
20.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光による大腸癌の光受容体をターゲットとした治療法の開発, 第85回日本臨床外科学会総会, Nov. 2023.
21.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術のトレーニングプログラム, 第85回日本臨床外科学会総会, Nov. 2023.
22.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔)の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
23.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 右側結腸癌に対するロボット支援下手術の可能性∼腹腔鏡手術との比較から∼, 第85回日本臨床外科学会総会, Nov. 2023.
24.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門アプローチを併用したロボット支援下直腸切除術の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
25.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 上部胃癌に対するロボット支援手術の工夫と成績, 第85回日本臨床外科学会総会, Nov. 2023.
26.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第85回日本臨床外科学会総会, Nov. 2023.
27.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
28.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
29.	Toshiaki Yoshimoto : Bevacizumab使用中の消化器外科手術についての検討, 第15回日本Acute Care Surgery学会学術集会, Oct. 2023.
30.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種特異的なエクソソーム中miRNAの同定, 第82回日本癌学会学術総会, Sep. 2023.
31.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化-Left-handed LCS and pincer approach-, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
32.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸内細菌叢の変化からみた減量・代謝改善手術の効果, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
33.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 大建中湯の消化器疾患における役割, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
34.	Toshiaki Yoshimoto, Masaaki Nishi, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LEDによる大腸癌由来CAF制御および抗腫瘍効果, 第78回日本消化器外科学会総会, Jul. 2023.
35.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いた胃癌腹膜播種の予測, 第78回日本消化器外科学会総会, Jul. 2023.
36.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第78回日本消化器外科学会総会, Jul. 2023.
37.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第78回日本消化器外科学会総会, Jul. 2023.
38.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第78回日本消化器外科学会総会, Jul. 2023.
39.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第78回日本消化器外科学会総会, Jul. 2023.
40.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援手術の有用性, 第78回日本消化器外科学会総会, Jul. 2023.
41.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチを用いた拡大骨盤手術手技, 第78回日本消化器外科学会総会, Jul. 2023.
42.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 大腸癌におけるFrailの意義と免疫栄養指標との関連, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
43.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌術前における栄養，リハビリ介入の検討, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
44.	Takayuki Noma, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 切除不能進行胃癌に対してSOX-NIVO後Conversion手術を施行した2症例, 第44回癌免疫外科研究会, Jun. 2023.
45.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 女性消化器外科医の技術向上とキャリア育成を目指した取り組み, 日本消化器病学会四国支部第119回例会, Jun. 2023.
46.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Correlation of Immunoscore and Frailty in Colorectal Cancer, 第48回日本外科系連合学会学術集会, Jun. 2023.
47.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性, 第48回日本外科系連合学会学術集会, Jun. 2023.
48.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット支援下手術(経裂孔)の有用性, 第32回日本癌病態治療研究会, Jun. 2023.
49.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット支援胃癌手術の手術手技, 第77回手術手技研究会, May 2023.
50.	仲須千春, Masaaki Nishi, Yuji Morine, Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Mitsuo Shimada : 青色LEDを用いたCAFの糖代謝に着目した腫瘍免疫制御のメカニズムの解明, 第123回日本外科学会定期学術集会, Apr. 2023.
51.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動リハビリの意義: 短期成績を改善するが長期成績には寄与しない, 第123回日本外科学会定期学術集会, Apr. 2023.
52.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌フレイル患者における術前栄養リハビリ介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
53.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸脳相関からみたMetabolic surgeryの術後早期血糖抑制効果, 第123回日本外科学会定期学術集会, Apr. 2023.
54.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach, 第123回日本外科学会定期学術集会, Apr. 2023.
55.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 下部直腸癌に対する経肛門アプローチにおける術中ホログラム手術支援の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
56.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光の腫瘍微小環境に対する効果, 第123回日本外科学会定期学術集会, Apr. 2023.
57.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するMRIを用いた骨盤神経描出, 第123回日本外科学会定期学術集会, Apr. 2023.
58.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績 ∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2023.
59.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット手術の有用性, 第95回日本胃癌学会総会, Feb. 2023.
60.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第95回日本胃癌学会総会, Feb. 2023.
61.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : MISによる胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第95回日本胃癌学会総会, Feb. 2023.
62.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するホログラムを駆使した新たな経肛門手術, 第266回徳島医学会学術集会, Feb. 2023.
63.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後に発症した鼠径ヘルニアに対する腹腔鏡手術症例の検討, 第35回日本内視鏡外科学会総会, Dec. 2022.
64.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
65.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門側方リンパ節郭清の手技と短期成績 ∼ホログラムシミュレーションの有用性∼, 第35回日本内視鏡外科学会総会, Dec. 2022.
66.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃切除における6番リンパ節郭清困難性の術前予測, 第35回日本内視鏡外科学会総会, Dec. 2022.
67.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 食道胃接合部癌に対するロボット支援下手術(経裂孔)の工夫, 第35回日本内視鏡外科学会総会, Dec. 2022.
68.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 低侵襲胃全摘術後再建における肝臓脱転による視野確保とOrVil法の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
69.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子および追加切除例の検討, 第84回日本臨床外科学会総会, Nov. 2022.
70.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌に対する術前化学放射線療法におけるADC値の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
71.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
72.	Toshihiro Nakao, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下結腸癌手術における体腔内吻合の短期成績, 第84回日本臨床外科学会総会, Nov. 2022.
73.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第84回日本臨床外科学会総会, Nov. 2022.
74.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Yuuma Wada, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化- Left-handed LCS and pincer app roach –, 第84回日本臨床外科学会総会, Nov. 2022.
75.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第84回日本臨床外科学会総会, Nov. 2022.
76.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
77.	Kouzou Yoshikawa, Mitsuo Shimada, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第52回胃外科・術後障害研究会, Nov. 2022.
78.	Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発 -フラボノイド(EGCGとSudachitin)の可能性-, 第33回日本消化器癌発生学会総会, Nov. 2022.
79.	Takuya Tokunaga, Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 腫瘍関連マクロファージおよび大腸癌に対する青色LEDの効果, 第33回日本消化器癌発生学会総会, Nov. 2022.
80.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとFrailの相関についての検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
81.	Masaaki Nishi, Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Yuuma Wada, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 漢方とBacterial translocation-大建中湯の消化管疾患に対する多面的効果の検討-, 第35回日本外科感染症学会総会学術集会, Nov. 2022.
82.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満肝細胞癌患者に対する術前栄養運動介入の有用性 -ERAS導入による手術成績の向上-, 第60回日本癌治療学会学術集会, Oct. 2022.
83.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 大腸癌手術における予後因子としてのFrailの意義, 第60回日本癌治療学会学術集会, Oct. 2022.
84.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
85.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット手術の工夫 Pincer approach to gastrosplenic ligament, 第60回日本癌治療学会学術集会, Oct. 2022.
86.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : ハイブリッド側方リンパ節郭清手技と短期成績∼ホログラムシミュレーションの有用性∼, 第60回日本癌治療学会学術集会, Oct. 2022.
87.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌における術前化学放射線療法においてADC値の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
88.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 大腸癌におけるImmunosoreとFrailの相関, 第60回日本癌治療学会学術集会, Oct. 2022.
89.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第60回日本癌治療学会学術集会, Oct. 2022.
90.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
91.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤直腸癌に対するTpAPR手術手技, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
92.	Yuuma Wada, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 癌関連線維芽細胞における糖代謝に着目した治療法の可能性, 第81回日本癌学会学術総会, Sep. 2022.
93.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
94.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Yuuma Wada, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌におけるロボット支援胃癌手術の工夫, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
95.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
96.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下結腸癌手術における体腔内吻合の短期成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
97.	Masaaki Nishi, Shuhai Chen, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発-フラボノイド(EGCGとSudachitin)の可能性-, 第265回徳島医学会学術集会, Jul. 2022.
98.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
99.	岩川陽介, Masaaki Nishi, Yuuma Wada, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 胃GISTに対するLECSの検討 -腫瘍径5㎝以上に対するLECS-, 第77回日本消化器外科学会総会, Jul. 2022.
100.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Hologramによるシミュレーションを用いた経肛門的側方リンパ節郭清, 第77回日本消化器外科学会総会, Jul. 2022.
101.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平 and Mitsuo Shimada : 大腸癌腫瘍関連マクロファージに対する青色LEDの効果, 第77回日本消化器外科学会総会, Jul. 2022.
102.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and 岩川陽介 : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
103.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
104.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuuma Wada and 山下祥子 : 上部胃癌に対するロボット支援胃癌手術の工夫, 第77回日本消化器外科学会総会, Jul. 2022.
105.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 胃癌播種診断におけるCTスコアリングシステムを用いた診断率改善の試み, 第77回日本消化器外科学会総会, Jul. 2022.
106.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第31回日本癌病態治療研究会, Jun. 2022.
107.	Yuuma Wada, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 進行胃癌に対するロボット支援下胃切除術の有用性, 第117回例会日本消化器病学会四国支部, Jun. 2022.
108.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 進行胃癌に対するロボット支援胃切除術の有用性とピットフォール, 第47回日本外科系連合学会学術集会, Jun. 2022.
109.	Toshiaki Yoshimoto, Takuya Tokunaga, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, 山下祥子, 岩川陽介 and Mitsuo Shimada : Intraoperative holographic image-guided lateral pelvic lymph node dissection in a transanal approach for rectal cancer, CARS 2022, Jun. 2022.
110.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチ併用ハイブリッド側方リンパ節郭清に対するホログラムの有用性, 第31回日本コンピュータ外科学会大会, Jun. 2022.
111.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : Apparent diffusion coefficient measurements predict survival outcomes after neoadjuvant chemoradiotherapy in locally advanced rectal cancer, 第67回国際外科学会日本部会総会, Jun. 2022.
112.	Toshiaki Yoshimoto, Hideya Kashihara, Kouzou Yoshikawa, Hiroki Ishibashi and Mitsuo Shimada : ロボット支援下前立腺全摘後の鼠径ヘルニアに対する腹腔鏡手術症例の検討, 第20回日本ヘルニア学会学術集会, Jun. 2022.
113.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ロボット胃癌手術における工夫 -Left handed LCS techniqueとPincer approach for gastro-splenic ligament-, 第76回手術手技研究会, May 2022.
114.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 術前抗がん剤治療を行った進行胃癌に対する低侵襲手術の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
115.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2022.
116.	Yoshihito Matsuzaki, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ALS患者の胃癌2切除例, 第122回日本外科学会定期学術集会, Apr. 2022.
117.	Yuuma Wada, Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第122回日本外科学会定期学術集会, Apr. 2022.
118.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and 岩川陽介 : 大腸癌におけるImmunoscoreとフレイルの検討, 第122回日本外科学会定期学術集会, Apr. 2022.
119.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性 - TaTME併用腹腔鏡下直腸切除術との比較から –, 第122回日本外科学会定期学術集会, Apr. 2022.
120.	武原悠花子, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入術前減量プログラムの有用, 第122回日本外科学会定期学術集会, Apr. 2022.
121.	山下祥子, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 岩川陽介 : 直腸癌の放射線化学療法における肥満細胞の役割, 第122回日本外科学会定期学術集会, Apr. 2022.
122.	沖川昌平, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
123.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平, 山下祥子, 岩川陽介 and Mitsuo Shimada : 青色LEDの腫瘍関連マクロファージ(TAM)および大腸癌細胞に対する効果, 第122回日本外科学会定期学術集会, Apr. 2022.
124.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and 山下祥子 : ロボット支援胃癌手術の短期・長期成績-ロボットvs腹腔鏡:プロペンシティスコアマッチ解析-, 第122回日本外科学会定期学術集会, Apr. 2022.
125.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第94回日本胃癌学会総会, Mar. 2022.
126.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 高齢者におけるFrailtyの臨床的意義, 第94回日本胃癌学会総会, Mar. 2022.
127.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity score-matched analysis of the short-and long-term outcomes of RG vs. LG, 第94回日本胃癌学会総会, Mar. 2022.
128.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : The usefulness of the minimal invasive surgery for advanced gastric cancer with preoperative chemotherapy, 第94回日本胃癌学会総会, Mar. 2022.
129.	Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腸管Microbiome解析からみた大建中湯の消化管疾患に対する多面的効果の検討, 第18回日本消化管学会総会学術集会(GI Week 2022), Feb. 2022.
130.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : ロボット支援下前立腺全摘術後に発症した鼠径ヘルニアの検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
131.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡・ロボット支援下胃癌手術のトレーニングプログラムの構築, 第34回日本内視鏡外科学会総会, Dec. 2021.
132.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第34回日本内視鏡外科学会総会, Dec. 2021.
133.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : NASHに対する新たな治療アプローチとしての腹腔鏡下スリーブ状胃切除術, 第34回日本内視鏡外科学会総会, Dec. 2021.
134.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の有用性, 第34回日本内視鏡外科学会総会, Dec. 2021.
135.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 横行結腸・脾弯曲部・下行結腸癌における血管走行と腹腔鏡下手術手技に関する検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
136.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 他臓器合併切除を要する直腸癌に対するTrasaperineal abdominoperineal resection, 第34回日本内視鏡外科学会総会, Dec. 2021.
137.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性(WS5-2), 第34回日本内視鏡外科学会総会, Dec. 2021.
138.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : ロボット支援胃癌手術におけるLeft hand LCS techniqueを用いた定型化への取り組み(WS6-7), 第34回日本内視鏡外科学会総会, Dec. 2021.
139.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 青色LEDの癌関連線維芽細胞および大腸癌に対する効果, 第32回日本消化器癌発生学会総会, Nov. 2021.
140.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Shoko Yamashita, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and IWAKAWA Yosuke : 直腸癌の放射線化学療法における肥満細胞の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
141.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : EGCGがCAFの糖代謝を標的とし，腫瘍悪性度を抑制する, 第32回日本消化器癌発生学会総会, Nov. 2021.
142.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 直腸癌に対する経肛門的アプローチにおけるホログラムと尿道造影を併用した術中ナビゲーション, 第30回日本コンピュータ外科学会大会, Nov. 2021.
143.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃切除の有用性-Robotic Versus Laparoscopic Gastrectomy: Propensi ty-Matched Analysis.-, 第116回日本消化器病学会四国支部例会, Nov. 2021.
144.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : taTMEの手術手技と治療成績, 第116回日本消化器病学会四国支部例会, Nov. 2021.
145.	IWAKAWA Yosuke, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 胃原発の未分化型多形肉腫の1例, 第83回日本臨床外科学会総会, Nov. 2021.
146.	Shoko Yamashita, Masaaki Nishi, Toshiaki Yoshimoto, Yuuma Wada, Hideya Kashihara, Chie Takasu, Toshihiro Nakao, Takuya Tokunaga, Kouzou Yoshikawa, Koichi Tsuneyama and Mitsuo Shimada : Osteoclast-like giant cellを伴うhamartomatous inverted polypから発生したリンパ球浸潤胃癌の一例, 第83回日本臨床外科学会総会, Nov. 2021.
147.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第83回日本臨床外科学会総会, Nov. 2021.
148.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 大腸癌予後因子としてのFrailの意義, 第83回日本臨床外科学会総会, Nov. 2021.
149.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の標準化, 第83回日本臨床外科学会総会, Nov. 2021.
150.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 直腸切断術に対するTransperineal approachの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
151.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡下胃癌手術における術前減量プログラムの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
152.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 経肛門的内視鏡下直腸間膜切除術TaTME併用による安全なロボット支援下直腸切除術の導入, 第83回日本臨床外科学会総会, Nov. 2021.
153.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 横行結腸癌における中結腸動脈の分岐からみた腹腔鏡下手術手技，治療成績, 第83回日本臨床外科学会総会, Nov. 2021.
154.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 腹腔鏡下胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第83回日本臨床外科学会総会, Nov. 2021.
155.	Chie Takasu, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and NAKASU Chiharu : 地方だからこそ発信できるインクルージョンを目指した働き方改革, 第83回日本臨床外科学会総会, Nov. 2021.
156.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : ロボット時代の正確な腹膜播種診断に向けての胃癌Staging laparoscopyの有用性, JDDW 2021, Nov. 2021.
157.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : 外科手術におけるFrailtyの重要性, 第51回胃外科・術後障害研究会, Nov. 2021.
158.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, IWAKAWA Yosuke and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子:追加切除例の検討, 第59回日本癌治療学会学術集会, Oct. 2021.
159.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 高齢者胃癌患者における外科手術の意義-Frailtyの重要性-, 第59回日本癌治療学会学術集会, Oct. 2021.
160.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 当科におけるTaTME手術手技と治療成績, 第59回日本癌治療学会学術集会, Oct. 2021.
161.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における多職種介入術前減量プログラムの有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
162.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 進行胃癌に対するロボット手術の有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
163.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yasuhiro Hamada : 肥満外科手術における術前NLRの有用性, 第27回外科侵襲とサイトカイン研究会, Oct. 2021.
164.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
165.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
166.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Shohei Okikawa and Mitsuo Shimada : 青色LEDの癌関連線維芽細胞および大腸癌細胞に対する効果, 第76回日本消化器外科学会総会, Jul. 2021.
167.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援胃切除術の有用性, 第76回日本消化器外科学会総会, Jul. 2021.
168.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : Feasibility of hybrid robotic rectal surgery with TaTME for lower rectal cancer, 第76回日本消化器外科学会総会, Jul. 2021.
169.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shohei Eto : 高齢者胃癌に対するFrailityの意義, 第76回日本消化器外科学会総会, Jul. 2021.
170.	Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : 地方外科の実情と今後のリーダー育成に向けて, 第76回日本消化器外科学会総会, Jul. 2021.
171.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 直腸癌に対するTaTMEの手術手技と治療成績, 第76回日本消化器外科学会総会, Jul. 2021.
172.	Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Okikawa, Shoko Yamashita, IWAKAWA Yosuke and NAKASU Chiharu : 青色LEDの癌関連線維芽細胞および大腸癌細胞に対する効果, 第115回日本消化器病学会四国支部例会, Jun. 2021.
173.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における術前減量プログラムは短期成績改善に寄与する, 第12回日本臨床栄養代謝学会首都圏支部会学術集会, May 2021.
174.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援下胃切除術の有用性と安全性, 第75回手術手技研究会, May 2021.
175.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Mitsuo Shimada : 大腸癌予後因子としてのFrailの意義とメカニズムの検討, 第107回日本消化器病学会総会, Apr. 2021.
176.	Jun Higashijima, Mitsuo Shimada, Shohei Okikawa, Toshiaki Yoshimoto, Shohei Eto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga and Kouzou Yoshikawa : 骨髄由来免疫抑制細胞を標的とした放射線治療抵抗性の制御メカニズムの解明, 第121回日本外科学会定期学術集会, Apr. 2021.
177.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Shohei Okikawa : 大腸癌および腫瘍微小環境に対する青色LEDの効果, 第121回日本外科学会定期学術集会, Apr. 2021.
178.	Shohei Eto, Kouzou Yoshikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Toshihiro Nakao, Takuya Tokunaga, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : ロボット支援腹腔鏡下前立腺切除術後の鼠径ヘルニア症例に対する治療戦略, 第121回日本外科学会定期学術集会, Apr. 2021.
179.	Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : 転移性肝癌におけるstromal PD-L1発現の意義, 第121回日本外科学会定期学術集会, Apr. 2021.
180.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : NASHに対する新たな治療アプローチとしてのmetabolic surgeryの可能性, 第121回日本外科学会定期学術集会, Apr. 2021.
181.	Takuya Tokunaga, Mitsuo Shimada, Yu Saitou, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and 杉本真樹 : ホログラムと術中尿道造影を駆使した経会陰的直腸切断術(TpAPR), 第121回日本外科学会定期学術集会, Apr. 2021.
182.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, K Yamaguchi, M Takahashi, Hiro-omi Kanayama and Mitsuo Shimada : Surgical approach for inguinal hernia following robot-assisted radical prostatectomy, 第33回日本内視鏡外科学会, Mar. 2021.
183.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : The Usefulness of Intraoperative Urethrography for Avoiding Urethral Injury in TpTME, 第33回日本内視鏡外科学会, Mar. 2021.
184.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Usefulness of a left handed LCS technique for robotic gastrectomy, 第33回日本内視鏡外科学会, Mar. 2021.
185.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of the OrVil method in LATG, 第33回日本内視鏡外科学会, Mar. 2021.
186.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Usefulness of preoperative NLR as a predictive marker of DM remission in sleeve gastrectomy, 第33回日本内視鏡外科学会, Mar. 2021.
187.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性, 第33回日本内視鏡外科学会, Mar. 2021.
188.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and Yuuma Wada : Robotic Versus Laparoscopic Gastrectomy: Propensity-Matched Analysis, 第93回日本胃癌学会総会, Mar. 2021.
189.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 地方におけるロボット手術の定型化への試み, 第93回日本胃癌学会総会, Mar. 2021.
190.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 肥満外科における術後体重減少・糖尿病寛解予測因子としてのNLRの有用性, 第57回日本外科代謝栄養学会学術集会, Dec. 2020.
191.	Toshiaki Yoshimoto, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yukako Takehara and Mitsuo Shimada : TaTMEを安全に行うために∼術中尿道造影の有用性∼, 第45回日本外科系連合学会学術集会, Dec. 2020.
192.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 鏡視下胃癌手術のトレーニングプログラムの構築Stepwise training programの有用性, 第45回日本外科系連合学会学術集会, Dec. 2020.
193.	Yukako Takehara, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : DST吻合における吻合部血流不全域のリスク因子:追加切除例の検討から, 第75回日本消化器外科学会総会, Dec. 2020.
194.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto, Yukako Takehara and Mitsuo Shimada : 直腸癌CRTにおける腫瘍のIDO発現の意義, 第75回日本消化器外科学会総会, Dec. 2020.
195.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 進行胃癌に対するロボット支援下胃切除術の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
196.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 肥満外科における術後体重減少・糖尿病寛解予測因子としてのNLRの有用性, 第75回日本消化器外科学会総会, Dec. 2020.
197.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援下胃癌手術におけるLeft handed LCS techniqueの有用性, 第75回日本消化器外科学会総会, Dec. 2020.
198.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : TpTMEにおける前壁側剥離の工夫 ∼術中尿道造影の有用性∼, 第75回日本消化器外科学会総会, Dec. 2020.
199.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
200.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Shohei Okikawa : 青色LEDによる大腸癌の光受容体をターゲットとする治療法の開発, 第31回日本消化器癌発生学会総会, Nov. 2020.
201.	Shohei Eto, Masaaki Nishi, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 下部進行直腸癌におけるCRT後のリンパ球CRP比(LCR)は予後不良因子となる, 第31回日本消化器癌発生学会総会, Nov. 2020.
202.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : The Usefulness of Intraoperative Urethrography in Transperineal total Mesorectal Excision, JDDW2020, Nov. 2020.
203.	Jun Higashijima, Toshiaki Yoshimoto, Shohei Eto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : ICG蛍光法を用いた大腸癌手術成績向上のための戦略, 第82回日本臨床外科学会総会, Oct. 2020.
204.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : ロボット支援胃癌手術の定型化-Left Handed LCS techniqueの有用性-, 第82回日本臨床外科学会総会, Oct. 2020.
205.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 肥満患者に対する術後合併症の回避を目指した術前減量プログラムの有用性, 第82回日本臨床外科学会総会, Oct. 2020.
206.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 術中尿道造影を併用したTpAPR手術手技, 第82回日本臨床外科学会総会, Oct. 2020.
207.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法―Tension free methodの有用性―, 第82回日本臨床外科学会総会, Oct. 2020.
208.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Bevacizumab使用中の消化器外科手術に関する検討, 第56回日本腹部救急医学会総会, Oct. 2020.
209.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : ロボット支援下胃切除術の安全な導入と定型化, 第106回日本消化器病学会総会, Aug. 2020.
210.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例における予後因子の検討, 第92回日本胃癌学会総会, Jul. 2020.
211.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第92回日本胃癌学会総会, Jul. 2020.
212.	Yukako Takehara, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : 大腸癌におけるFrailの意義とメカニズムの検討, 第53回制癌剤適応研究会, Feb. 2020.
213.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara and Mitsuo Shimada : Bevacizumab使用中の消化器外科手術に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
214.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 局所進行直腸癌に対する分子標的薬を加えた術前化学放射線療法の効果と感受性予測, 第53回制癌剤適応研究会, Feb. 2020.
215.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 経肛門的内視鏡下直腸間膜切除術TaTME併用ロボット支援下直腸切除術の有用性, 第34回四国内視鏡外科研究会, Feb. 2020.
216.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : ロボット支援下胃切除術の安全な導入と定型化, 第34回四国内視鏡外科研究会, Feb. 2020.
217.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第260回徳島医学学会学術集会, Feb. 2020.
218.	Toshiaki Yoshimoto, Yukako Takehara, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : LED光による新たな癌制御法の開発, 第260回徳島医学会学術集会, Feb. 2020.
219.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Yasuhiro Hamada : 非アルコール性脂肪肝炎(NASH)に対する新たな外科治療の開発, 第260回徳島医学会学術集会, Feb. 2020.
220.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Stepwise trainingとTaTME併用による安全なロボット支援下直腸切除術の導入, 第32回日本内視鏡外科学会総会, Dec. 2019.
221.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援胃癌手術におけるLeft handed approach の有用性, 第32回日本内視鏡外科学会総会, Dec. 2019.
222.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : TpTMEを安全に行うために ∼前壁剥離時の術中尿道造影の有用性∼, 第32回日本内視鏡外科学会総会, Dec. 2019.
223.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : スリーブ状胃切除における多職種介入術前減量入院の効果, 第32回日本内視鏡外科学会総会, Dec. 2019.
224.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : The significance of metabolic surgery in the treatment for NASH, JDDW2019, Nov. 2019.
225.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 大腸切除術における他職種介入SSI対策チームの有用性, 第81回日本臨床外科学会総会, Nov. 2019.
226.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 直腸癌手術におけるICG蛍光法・サーモグラフィによる血流評価を用いた縫合不全回避対策, 第81回日本臨床外科学会総会, Nov. 2019.
227.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援下胃癌手術におけるLeft handed approach の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
228.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Yuji Morine and Mitsuo Shimada : 光受容体Opsin3をターゲットとした青色LEDの大腸癌抑制効果, 第81回日本臨床外科学会総会, Nov. 2019.
229.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 地方から発信する腹腔鏡技術認定医取得への教育プログラム, 第81回日本臨床外科学会総会, Nov. 2019.
230.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
231.	Toshiaki Yoshimoto, Masaaki Nishi, Yukako Takehara, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌のsidednessからみた腫瘍免疫, 第30回日本消化器癌発生学会総会, Nov. 2019.
232.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Katsuki Miyazaki : 下部直腸癌に対する経肛門的アプローチ(TaTME)∼術中尿道造影の有用性∼, 第112回日本消化器病学会四国支部例会, Nov. 2019.
233.	Kouzou Yoshikawa, Mitsuo Shimada, Hideya Kashihara, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Yasuhiro Hamada and Sumiko Yoshida : スリーブ状胃切除における術前減量入院の効果とNLRによる術後減量効果予測, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
234.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃切除術における術前減量プログラムの有用性, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
235.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : NASH治療におけるMetabolic surgeryの意義, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
236.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 胃癌に対するロボット手術の有用性, 第57回日本癌治療学会学術集会, Oct. 2019.
237.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Yuji Morine and Mitsuo Shimada : 光受容体Opn3を介した青色LEDの大腸癌抑制効果, 第57回日本癌治療学会学術集会, Oct. 2019.
238.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Katsuki Miyazaki and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, Oct. 2019.
239.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第55回日本胆道学会学術集会, Oct. 2019.
240.	Toshiaki Yoshimoto, Mitsuo Shimada, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani and Kouzou Yoshikawa : 光受容体Opn3を介した青色LED光の大腸癌抑制効果, 第78回日本癌学会学術総会, Sep. 2019.
241.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : GISTとの鑑別を要したデスモイド型線維腺腫症の一例, 第71回日本消化器画像診断研究会, Sep. 2019.
242.	Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Yukako Takehara : 術前診断が困難であった成人小腸重複腸管の1例, 第71回日本消化器画像診断研究会, Sep. 2019.
243.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Mitsuo Shimada : Bevacizumab使用中の消化器外科手術に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
244.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Left handed approach によるロボット支援下胃癌手術, 第74回日本消化器外科学会総会, Jul. 2019.
245.	Chie Takasu, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Toshiaki Yoshimoto : 女性消化器外科医の技術向上とキャリア育成を目指した取り組み, 第74回日本消化器外科学会総会, Jul. 2019.
246.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Urethrography navigationを用いたTpTME手術手技, 第74回日本消化器外科学会総会, Jul. 2019.
247.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性―合併症ゼロを目指した工夫―, 第74回日本消化器外科学会総会, Jul. 2019.
248.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Left handed approachによるロボット支援下胃癌手術, 第111回日本消化器病学会四国支部例会, Jun. 2019.
249.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : DWI-MRIのADC値を用いたSorafenibの効果予測に関する検討, 第20回日本肝がん分子標的治療研究会, Jun. 2019.
250.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Shoko Iwahashi : 大腸癌手術における周術期VTE予防マネジメント, 第44回日本外科系連合学会学術集会, Jun. 2019.
251.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
252.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TpTMEにおける前壁剥離時の術中尿道造影の有用性, 第73回手術手技研究会, May 2019.
253.	Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : NASH治療におけるMetabolic surgeryの意義, 第105回日本消化器病学会総会, May 2019.
254.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第105回日本消化器病学会総会, May 2019.
255.	仲須千春, Masaaki Nishi, Mitsuo Shimada, Shoko Iwahashi, Tetsuya Ikemoto, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 大腸癌手術における周術期VTE予防マネジメント, 第119回日本外科学会定期学術集会, Apr. 2019.
256.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 直腸切断術におけるTaTMEの工夫 ∼尿道損傷回避のための術中尿道造影の有用性∼, 第119回日本外科学会定期学術集会, Apr. 2019.
257.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Step-wise trainingシステムによる安全なロボット支援胃切除導入の取り組み, 第119回日本外科学会定期学術集会, Apr. 2019.
258.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構は原発巣と異なる可能性がある, 第119回日本外科学会定期学術集会, Apr. 2019.
259.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
260.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Yuuma Wada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 青色LED光のOpn3を介した大腸癌抑制効果 (第2報), 第119回日本外科学会定期学術集会, Apr. 2019.
261.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 癌微小環境における大建中湯の肝星細胞活性化制御・癌細胞オートファジーを介した癌細胞増殖抑制効果, 第119回日本外科学会定期学術集会, Apr. 2019.
262.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Shoko Iwahashi, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第119回日本外科学会定期学術集会, Apr. 2019.
263.	Shuichi Iwahashi, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 臨床応用に向けたインスリン産生細胞分化誘導に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
264.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
265.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuji Morine and Mitsuo Shimada : 大腸癌に対する青色LED光の光受容体を介した抗腫瘍効果, 第52回制癌剤適応研究会, Mar. 2019.
266.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Toshiaki Yoshimoto : 肝胆膵領域癌におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第52回制癌剤適応研究会, Mar. 2019.
267.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of our step-wise training system for robotic assisted gastrectomy., 第91回日本胃癌学会総会, Feb. 2019.
268.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 腹腔鏡下胃癌手術のトレーニングプログラムの構築, 第91回日本胃癌学会総会, Feb. 2019.
269.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TaTMEにおける尿道損傷回避のための工夫 ∼術中尿道造影の有用性∼, 第33回四国内視鏡外科研究会, Feb. 2019.
270.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 安全なロボット支援下胃癌手術の再導入, 第2回徳島外科医会, Feb. 2019.
271.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Lenvatinib投与中に呼吸不全を併発し急激な悪化の転機をたどった肝細胞癌多発肺転移の1例, 第2回徳島外科医会, Feb. 2019.
272.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TaTMEにおける尿道損傷回避のための術中尿道造影の有用性, 第31回日本内視鏡外科学会総会, Dec. 2018.
273.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 大腸癌切除不能両葉多発肝転移におけるConversion後予後に関する検討-FOLFOXIRI療法の有用性-, 第80回日本臨床外科学会総会, Nov. 2018.
274.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Toshiaki Yoshimoto : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第10回膵臓内視鏡外科研究会・第12回肝臓内視鏡外科研究会, Nov. 2018.
275.	Jun Higashijima, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa and Mitsuo Shimada : Crohn's disease の外科治療成績について -Kono-S吻合の有用性-, 第110回日本消化器病学会四国支部例会, Nov. 2018.
276.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Rui Feng, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第29回日本消化器癌発生学会総会, Nov. 2018.
277.	Hideya Kashihara, Toshiaki Yoshimoto, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : 大腸癌に対する青色LED光の効果と光受容体の関与についての研究, 第29回日本消化器癌発生学会総会, Nov. 2018.
278.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto and Shogo Oota : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第56回日本癌治療学会学術集会, Oct. 2018.
279.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下前方切除術におけるICG蛍光法・サーモグラフィーによる血流評価の有用性, 第56回日本癌治療学会学術集会, Oct. 2018.
280.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Toshiaki Yoshimoto, Yuuma Wada and Shogo Oota : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第27回消化器疾患病態治療研究会, Sep. 2018.
281.	Toshiaki Yoshimoto, Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Nrf2に着目した肝癌細胞における腫瘍関連マクロファージ活性化の検討, 第18回日本肝がん分子標的治療研究会, Jul. 2018.
282.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第76回日本癌学会学術総会, Sep. 2017.
283.	Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Shogo Oota : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第255回徳島医学会学術集会, Aug. 2017.
284.	Daichi Ishikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌の発癌・癌進展におけるmicroRNA-449aの役割解明, 第72回日本消化器外科学会総会, Jul. 2017.
285.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : 下部直腸癌のCRT後NLRは予後不良因子になる, 第72回日本消化器外科学会総会, Jul. 2017.
286.	Yu Saitou, Mitsuo Shimada, 瓜生原葉子, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第72回日本消化器外科学会総会, Jul. 2017.
287.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : One stop shopを目指したEOB-MRIによる部分肝機能評価, 第72回日本消化器外科学会総会, Jul. 2017.
288.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Jun Higashijima : 大腸癌肝転移に切除基準と腫瘍悪性度評価, 第72回日本消化器外科学会総会, Jul. 2017.
289.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, Toshiaki Yoshimoto, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 日本外科代謝栄養学会第54回学術集会, Jul. 2017.
290.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Koichi Tsuneyama : 症例, 第53回日本肝癌研究会, Jul. 2017.
291.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : 術前Prognostic nutritional index(PNI)は肝癌術後短期・長期予後予測因子になる, 第53回日本肝癌研究会, Jul. 2017.
292.	Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ntermediate stage肝癌に対する肝切除の有用性, 第53回日本肝癌研究会, Jul. 2017.
293.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光の光受容体(opsin)を介した癌細胞増殖抑制効果の検討, 第42回日本外科系連合学会学術集会, Jun. 2017.
294.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Stylization of laparoscopic surgery using 3D simulation for young surgeo, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
295.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
296.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第35回日本肝移植研究会, Jun. 2017.
297.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第26回日本癌病態治療研究会, Jun. 2017.
298.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 肝葉切除術後に施行した膵切除術2例の経験, 第71回手術手技研究会, May 2017.
299.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胃切除術における肥満の影響と治療成績改善への取り組み, 第117回日本外科学会定期学術集会, Apr. 2017.
300.	宮崎克己, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例, 第117回日本外科学会定期学術集会, Apr. 2017.
301.	Shogo Oota, Yuji Morine, Masato Yoshikawa, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 膵癌術後残膵再発に対する再切除導入効果の検証, 第117回日本外科学会定期学術集会, Apr. 2017.
302.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第117回日本外科学会定期学術集会, Apr. 2017.
303.	Hiroki Teraoku, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における膵全摘症例の検討-術後短期成績・長期予後の両面に着目して-, 第117回日本外科学会定期学術集会, Apr. 2017.
304.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 肝細胞に対するROS/ ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第117回日本外科学会定期学術集会, Apr. 2017.
305.	Daichi Ishikawa, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第117回日本外科学会定期学術集会, Apr. 2017.
306.	川下陽一郎, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, Apr. 2017.
307.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : Cancer-associated fibroblastsを介した膵癌細胞におけるnab-paclitaxelの効果, 第117回日本外科学会定期学術集会, Apr. 2017.
308.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞による腫瘍免疫状態を反映する免疫学的バイオマーカー探索, 第117回日本外科学会定期学術集会, Apr. 2017.
309.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, Apr. 2017.
310.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第117回日本外科学会定期学術集会, Apr. 2017.
311.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, 梶浦大資, 多々納浩, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 第117回日本外科学会定期学術集会, Apr. 2017.
312.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるHeat shock factor 1(HSF1)発現の意義, 第50回制癌剤適応研究会, Mar. 2017.
313.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3陽性調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第50回制癌剤適応研究会, Mar. 2017.
314.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Hideya Kashihara, Takuya Tokunaga, Chie Takasu, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Indoleamine 2,3-dioxygenase(IDO)による胃癌再発機構, 第50回制癌剤適応研究会, Mar. 2017.
315.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Toshiaki Yoshimoto, Masato Yoshikawa, Yu Saitou, Yuji Morine and Satoru Imura : 8 ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第44回日本膵・膵島移植研究会, Mar. 2017.
316.	Shuichi Iwahashi, Mitsuo Shimada, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 465nm-LED光照射による癌幹細胞制御に関する研究, 第16回日本再生医療学会総会, Mar. 2017.
317.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Yu Saitou and Toshiaki Yoshimoto : ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第16回日本再生医療学会総会, Mar. 2017.
318.	Toshiaki Yoshimoto, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例-切除肝・病理解剖をふまえて-, 第66回日本消化器画像診断研究会, Feb. 2017.
319.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第66回日本消化器画像診断研究会, Feb. 2017.
320.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 膵腫瘍性病変におけるType1 regulatory T細胞の臨床的有用性の検討-Type1 regulatory T細胞は診断・再発予測バイオマーカーとして有用である-, 第254回徳島医学会学術集会, Feb. 2017.
321.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部胆管癌超ハイリスク症例に対して根治術施行し術後管理, 第25回徳島外科術後管理研究会, Feb. 2017.
322.	Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Atsushi Takata, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Long-term survivors of HCC using sorafenib, 2nd Eastern &Western Association Liver Tumors(EWALT), Jan. 2017.
323.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
324.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞に対するROS/ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第46回日本創傷治癒学会, Dec. 2016.
325.	Masato Yoshikawa, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第25回日本コンピュータ外科学会大会, Nov. 2016.
326.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, 馮睿, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : LED光の癌細胞および正常細胞に対する効果, 第25回日本コンピュータ外科学会大会, Nov. 2016.
327.	Toshiaki Yoshimoto, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除限界予測の可能性, 第78回日本臨床外科学会総会, Nov. 2016.
328.	Masato Yoshikawa, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 再発膵癌に対する再切除の有用性の検討, 第78回日本臨床外科学会総会, Nov. 2016.
329.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における若手医師の腹腔鏡手術トレーニングの現状と効果, 第78回日本臨床外科学会総会, Nov. 2016.
330.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 若手外科医でも安全・確実に施行できる肝葉切除術, 第78回日本臨床外科学会総会, Nov. 2016.
331.	Yu Saitou, Yuji Morine, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 膵頭十二指腸切除術に対するModified de-rotation法を用いた`` Complete artery-f irst approach'', 第78回日本臨床外科学会総会, Nov. 2016.
332.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 膵全摘における人工膵臓の有用性における検討, 第78回日本臨床外科学会総会, Nov. 2016.
333.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 当科における切除不能・再発進行膵癌に対する治療成績, 第54回日本癌治療学会学術集会, Oct. 2016.
334.	Daichi Ishikawa, 川下陽一郎, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : FBXW7発現は転移性肝癌における切除後再発予測因子となる, 第54回日本癌治療学会学術集会, Oct. 2016.
335.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, Oct. 2016.
336.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, Oct. 2016.
337.	Toshiaki Yoshimoto, Yu Saitou, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第52回日本移植学会総会, Sep. 2016.
338.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 脂肪由来幹細胞によるInsulin-producing cell作成における新規分化誘導方法に関する検討, 第52回日本移植学会総会, Sep. 2016.
339.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 術前診断が困難であった肝偽リンパ腫の1例, 第65回日本消化器画像診断研究会, Sep. 2016.
340.	Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第11回肝癌治療シミュレーション研究会, Sep. 2016.
341.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する, 第35回Microwave Surgery研究会, Sep. 2016.
342.	馮睿, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata and Toshiaki Yoshimoto : Cancer-associated fibroblastsに着目した膵癌細胞におけるnab-paclitaxcelの効果, 第27回日本消化器癌発生学会総会, Sep. 2016.
343.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第27回日本消化器癌発生学会総会, Sep. 2016.
344.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 消化器癌における末梢血Tr1細胞とFoxp3調節性T細胞の有用性の検討, 第27回日本消化器癌発生学会総会, Sep. 2016.
345.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果, 第27回日本消化器癌発生学会総会, Sep. 2016.
346.	Hideya Kashihara, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : IDOによる免疫能と大腸癌転移機構, 第27回日本消化器癌発生学会総会, Sep. 2016.
347.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第91回中国四国外科学会総会/第21回中国四国内視鏡外科研究会, Sep. 2016.
348.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
349.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Yuji Morine, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Hiroki Teraoku : 青色LED光は癌細胞増殖を抑制する., 第71回日本消化器外科学会総会, Jul. 2016.
350.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Toshiaki Yoshimoto, Yuji Morine and Mitsuo Shimada : 大建中湯(TU-100)はTLR4/TNFαを介して総胆管結紮ラットモデルにおける肝障害を抑制する., 第23回外科侵襲とサイトカイン研究会, Jul. 2016.
351.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果, 第23回外科侵襲とサイトカイン研究会, Jul. 2016.
352.	Masato Yoshikawa, Yu Saitou, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ABO不適合生体肝移植後にCMV感染治療に難渋した一例., 第34回日本肝移植研究会, Jul. 2016.
353.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : NO阻害と転写活性制御からの虚血再灌流障害., 第34回日本肝移植研究会, Jul. 2016.
354.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, Jul. 2016.
355.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Atsushi Takata : 症例, 第52回日本肝癌研究会, Jul. 2016.
356.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Yu Saitou, Masato Yoshikawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Daichi Ishikawa, Shuichi Iwahashi and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果., 第105回日本消化器病学会四国支部例会, Jun. 2016.
357.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 切除不能・再発進行膵癌に対する治療成績., 第105回日本消化器病学会四国支部例会, Jun. 2016.
358.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : ノンテクニカルスキルを含めた総合手術技能評価法の開発., 第105回日本消化器病学会四国支部例会, Jun. 2016.
359.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
360.	Toshiaki Yoshimoto, C Enkbold, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌における細胞周期調節因子Fbxw7発現低下の臨床病理学的意義., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
361.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
362.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
363.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
364.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Chie Takasu, Jun Higashijima, 川下陽一郎, Atsushi Takata, Toshiaki Yoshimoto, Satoru Imura and Mitsuo Shimada : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
365.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, May 2016.
366.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, Apr. 2016.
367.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, Apr. 2016.
368.	Hideya Kashihara, Mitsuo Shimada and Toshiaki Yoshimoto : NAFLD/NASHに対する治療オプションとしてのBariatric Surgeryの可能性-基礎から臨床へ-., 第102回日本消化器病学会総会, Apr. 2016.
369.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 直腸癌術前CRT症例におけるKi-67, Survivin発現の意義, 第102回日本消化器病学会総会, Apr. 2016.
370.	Shogo Oota, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Kouzou Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第116回日本外科学会定期学術集会, Apr. 2016.
371.	Shoko Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, Apr. 2016.
372.	関勇輔, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, Apr. 2016.
373.	Atsushi Takata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Chie Takasu : 腸管修復および癌幹細胞におけるSonic hedgehogの役割., 第116回日本外科学会定期学術集会, Apr. 2016.
374.	川下陽一郎, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto and Hirohisa Ogawa : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, Apr. 2016.
375.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 直腸癌術前CRT症例におけるKi-67，Survivin発現の意義, 第116回日本外科学会定期学術集会, Apr. 2016.
376.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, Apr. 2016.
377.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, Apr. 2016.
378.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kouzou Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性., 第116回日本外科学会定期学術集会, Apr. 2016.
379.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, Apr. 2016.
380.	布村俊幸, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 切除不能転移性肝癌を有する透析患者にFOLFOXIRI+Bevを施行しconversionが得られる1例., 第116回日本外科学会定期学術集会, Apr. 2016.
381.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 膵癌細胞におけるResveratrolのShh pathwayを介した細胞増殖抑制効果, 第116回日本外科学会定期学術集会, Apr. 2016.
382.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : 進行大腸癌に対する新たな予後予測因子の検討., 第116回日本外科学会定期学術集会, Apr. 2016.
383.	Jun Higashijima, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 側方転移を有する下部直腸癌への新たな治療戦略., 第116回日本外科学会定期学術集会, Apr. 2016.
384.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Masato Yoshikawa : 青色LED光は癌細胞増殖を抑制する., 第116回日本外科学会定期学術集会, Apr. 2016.
385.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 高齢者胃癌症例に対するリンパ節郭清範囲縮小の予後に及ぼす影響, 第88回日本胃癌学会総会, Mar. 2016.
386.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, Mar. 2016.

Et cetera, Workshop:

1.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 経肛門的内視鏡下直腸間膜切除術TaTME併用ロボット支援下直腸切除術の有用性, 日本消化器病学会四国支部第114回例会, Dec. 2020.
2.	Takuya Tokunaga, Mitsuo Shimada, Yu Saitou, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and 杉本真樹 : Trans-perineal APRにおける術前VR・MRシミュレーション, 第29回日本コンピュータ外科学会大会, Nov. 2020.
3.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例の検討, 第58回日本癌治療学会学術集会, Oct. 2020.
4.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : ロボット支援下胃切除術における左側LCSの有用性, 第58回日本癌治療学会学術集会, Oct. 2020.
5.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 進行胃癌に対するロボット支援下胃切除術の有用性-地方からの提言-, 第74回手術手技研究会, Oct. 2020.
6.	高橋叡, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Tetsuya Ikemoto : MRIが郭清範囲決定の一助となった早期胃癌の1例, 第120回日本外科学会定期学術集会, Aug. 2020.
7.	Yukako Takehara, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : 大腸癌におけるFrailの意義とメカニズムの検討, 第120回日本外科学会定期学術集会, Aug. 2020.
8.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yukako Takehara and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例の検討, 第120回日本外科学会定期学術集会, Aug. 2020.
9.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Yu Saitou, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and 杉本真樹 : 直腸切断術TpTMEにおける術前VR・MRシミュレーションと術中尿道造影ナビゲーションの有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
10.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における術前減量プログラムは短期成績改善に寄与する, 第120回日本外科学会定期学術集会, Aug. 2020.
11.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Yukako Takehara : 下部直腸癌CRT後リンパ球CRP比(LCR)は予後不良因子になる, 第120回日本外科学会定期学術集会, Aug. 2020.
12.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 胃癌術前T1N0症例における正診率向上の取り組み-的確なリンパ節郭清を目指して-, 第120回日本外科学会定期学術集会, Aug. 2020.
13.	Toshiaki Yoshimoto, Yukako Takehara, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : LED 光による新たな癌制御法の開発, 第261 回徳島医学会学術集会(令和 2 年度夏期), Aug. 2020.
14.	Chie Takasu, Hideya Kashihara, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Toshiaki Yoshimoto and Yukako Takehara : 経肛門的内視鏡下直腸間膜切除術 TaTME併用ロボット支援下直腸切除術の有用性, 第113回日本消化器病学会四国支部例会, Jun. 2020.
15.	Toshiaki Yoshimoto, Yuji Morine, Kouzou Yoshikawa, Masatake Akutagawa, Takahiro Emoto, Mitsuo Shimada and Yohsuke Kinouchi : Blue light emitting diodeによる大腸癌増殖制御効果, LED総合フォーラム2020 in 徳島, 129-130, Feb. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

免疫チェックポイント阻害薬治療時おけるhyperprogressinのメカニズムの解明 (Project/Area Number: 23K08091 )
光受容体Opsin3を介した青色LED光による消化器癌薬剤耐性解除に関する研究 (Project/Area Number: 22K16465 )
Search by Researcher Number (20758198)

Designated Assistant Professor : Yoshimoto, Toshiaki

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)